A O
54-year-old B-Age
woman B-Sex
with O
stage B-Detailed_description
IV I-Detailed_description
NSCLC B-Disease_disorder
was O
treated O
with O
carboplatin O
and O
paclitaxel O
without B-Detailed_description
disease I-Detailed_description
response I-Detailed_description
. O
Molecular B-Diagnostic_procedure
analysis I-Diagnostic_procedure
of O
tumor B-Diagnostic_procedure
tissue I-Diagnostic_procedure
was O
unavailable B-Detailed_description
at O
that O
time O
. O
However O
, O
her O
demographic O
profile O
( O
Asian O
, O
minimal B-Severity
smoking O
history O
, O
non-small B-Detailed_description
cell I-Detailed_description
histology B-Diagnostic_procedure
) O
predicted O
her O
disease O
would O
harbor O
EGFR B-Diagnostic_procedure
TKI I-Diagnostic_procedure
sensitive I-Diagnostic_procedure
cells I-Diagnostic_procedure
[ O
2 O
] O
. O
Therefore O
, O
she O
then O
initiated O
standard B-Detailed_description
daily O
dosing O
of O
erlotinib O
( O
150 B-Lab_value
mg I-Lab_value
) O
and O
her O
disease O
responded B-Detailed_description
. O
Twenty-eight B-Date
months I-Date
later I-Date
, O
she O
acquired O
resistance O
to O
erlotinib O
with O
progression B-Detailed_description
of O
disease O
systemically B-Detailed_description
. O
Following O
further O
progression O
through O
an O
experimental B-Detailed_description
angiogenesis O
inhibitor O
, O
she O
initiated O
pemetrexed O
and O
resumed O
standard O
dose O
erlotinib O
. O
After O
initial O
response O
, O
11 B-Date
months I-Date
later I-Date
, O
her O
disease O
again O
progressed B-Detailed_description
. O
DNA B-Biological_structure
was O
extracted O
from O
biopsy B-Diagnostic_procedure
of O
a O
progressing B-Detailed_description
lung B-Biological_structure
lesion B-Disease_disorder
and O
examined O
using O
established O
techniques O
for O
analysis O
of O
EGFR B-Diagnostic_procedure
mutations I-Diagnostic_procedure
[ O
5 O
] O
. O
Direct B-Diagnostic_procedure
sequencing I-Diagnostic_procedure
of O
exons B-Detailed_description
18 I-Detailed_description
– I-Detailed_description
21 I-Detailed_description
encoding O
the O
kinase B-Detailed_description
domain I-Detailed_description
of O
EGFR B-Diagnostic_procedure
revealed O
the O
L858R B-Diagnostic_procedure
mutation I-Diagnostic_procedure
associated O
with O
EGFR B-Detailed_description
TKI I-Detailed_description
sensitivity I-Detailed_description
( O
Fig. O
1 O
) O
[ O
2 O
] O
. O
It O
also O
demonstrated O
the O
T790M B-Diagnostic_procedure
mutation I-Diagnostic_procedure
associated O
with O
acquired B-Detailed_description
EGFR I-Detailed_description
TKI I-Detailed_description
resistance I-Detailed_description
( O
Fig. O
1 O
) O
[ O
2 O
] O
. O
She O
also O
developed O
headaches B-Sign_symptom
and O
there O
was O
a O
high O
clinical O
suspicion O
of O
CNS B-Biological_structure
metastases B-Disease_disorder
despite O
negative B-Lab_value
imaging B-Diagnostic_procedure
( O
not O
shown O
) O
. O
She O
refused O
a O
lumbar B-Therapeutic_procedure
puncture I-Therapeutic_procedure
. O
She O
initiated O
empiric B-Detailed_description
temozolomide O
plus O
standard B-Detailed_description
dose I-Detailed_description
erlotinib O
( O
150 O
mg O
daily O
) O
for O
presumed O
CNS B-Disease_disorder
disease I-Disease_disorder
, O
but O
after O
one O
cycle O
her O
headaches B-Sign_symptom
worsened B-Lab_value
, O
and O
she O
developed O
nausea B-Sign_symptom
and O
vomiting B-Sign_symptom
concerning O
for O
CNS B-Disease_disorder
metastases I-Disease_disorder
with O
associated O
raised B-Lab_value
intracranial B-Diagnostic_procedure
pressure I-Diagnostic_procedure
. O
Magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
( B-Diagnostic_procedure
MRI I-Diagnostic_procedure
) I-Diagnostic_procedure
of O
the O
brain B-Biological_structure
now O
demonstrated O
LM B-Disease_disorder
( O
Fig. O
2 O
) O
confirmed O
by O
CSF B-Diagnostic_procedure
cytology I-Diagnostic_procedure
( O
not O
shown O
) O
. O
By O
direct B-Detailed_description
sequencing B-Diagnostic_procedure
, O
DNA B-Biological_structure
from O
CSF B-Diagnostic_procedure
cells I-Diagnostic_procedure
harbored O
L858R B-Diagnostic_procedure
predicting O
EGFR B-Diagnostic_procedure
TKI I-Diagnostic_procedure
sensitivity I-Diagnostic_procedure
( O
Fig. O
3 O
, O
left O
panel O
) O
but O
not O
the O
T790M B-Diagnostic_procedure
resistance I-Diagnostic_procedure
mutation I-Diagnostic_procedure
( O
data O
not O
shown O
) O
. O
Because O
the O
result O
for O
T790M B-Diagnostic_procedure
was O
negative B-Lab_value
in O
this O
sample O
, O
we O
performed O
a O
more B-Lab_value
sensitive I-Lab_value
fluorescence B-Detailed_description
detection I-Detailed_description
PCR-based B-Detailed_description
assay B-Diagnostic_procedure
that O
takes O
advantage O
of O
a O
PCR B-Diagnostic_procedure
restriction I-Diagnostic_procedure
fragment I-Diagnostic_procedure
length I-Diagnostic_procedure
polymorphism I-Diagnostic_procedure
generated O
by O
the O
specific O
missense O
mutation O
( O
Fig. O
3 O
, O
right O
panel O
, O
arrow O
, O
positive O
control O
) O
[ O
6 O
] O
. O
That O
result O
was O
also O
negative B-Lab_value
, O
as O
only O
the O
wild B-Diagnostic_procedure
type I-Diagnostic_procedure
peak I-Diagnostic_procedure
was O
detected O
( O
Fig. O
3 O
, O
right O
panel O
, O
bottom O
) O
. O
Therefore O
, O
we O
hypothesized O
that O
the O
LM O
remained O
sensitive O
to O
an O
EGFR O
TKI O
if O
sufficiently O
high O
concentrations O
of O
drug O
could O
be O
achieved O
in O
the O
CSF O
. O
The O
erlotinib O
concentration O
required O
to O
inhibit O
growth O
of O
cell O
lines O
harboring O
L858R O
by O
50 O
% O
( O
IC50 O
) O
is O
100 O
nM O
( O
nM O
) O
[ O
2 O
] O
. O
Standard O
dose O
erlotinib O
( O
150 O
mg O
daily O
) O
achieves O
3000 O
nM O
in O
plasma O
[ O
7 O
] O
, O
but O
CSF O
concentrations O
of O
EGFR O
TKIs O
are O
as O
low O
as O
1 O
% O
plasma O
levels O
below O
the O
IC50 O
[ O
3 O
, O
8 O
] O
. O
Increasing O
the O
daily O
dose O
of O
gefitinib O
to O
enhance O
CSF O
penetration O
has O
been O
an O
effective O
strategy O
[ O
3 O
] O
, O
but O
gefitinib O
is O
no O
longer O
available O
in O
the O
United O
States O
following O
failure O
in O
phase O
III O
NSCLC O
trials O
. O
An O
analogous O
increase O
of O
the O
daily O
erlotinib O
dose O
above O
150 O
– O
200 O
mg O
daily O
induces O
unacceptable O
toxicity O
. O
However O
, O
weekly O
high-dose O
erlotinib O
up O
to O
2000 O
mg O
is O
tolerable O
[ O
4 O
] O
. O
Pharmacokinetic B-Diagnostic_procedure
analysis I-Diagnostic_procedure
of O
CSF B-Biological_structure
from O
another O
patient O
with O
NSCLC B-Disease_disorder
LM B-Disease_disorder
( O
not O
shown O
) O
treated O
with O
1500 O
mg O
erlotinib O
weekly O
demonstrated O
a O
peak B-Diagnostic_procedure
plasma I-Diagnostic_procedure
concentration I-Diagnostic_procedure
of O
11,300 B-Lab_value
nM I-Lab_value
with O
a O
concurrent O
CSF B-Diagnostic_procedure
concentration I-Diagnostic_procedure
of O
130 B-Lab_value
nM I-Lab_value
. O
Therefore O
, O
such O
high O
dose O
weekly O
administration O
of O
erlotinib O
achieved O
a O
CSF O
concentration O
exceeding B-Detailed_description
the I-Detailed_description
IC50 I-Detailed_description
. O
Therefore O
, O
to O
increase O
CSF O
penetrance O
over O
standard O
daily O
erlotinib O
dosing O
in O
this O
patient O
, O
we O
initiated O
high-dose O
weekly O
erlotinib O
at O
1000 B-Lab_value
mg I-Lab_value
then O
1200 B-Lab_value
mg I-Lab_value
; O
persistent B-Detailed_description
nausea B-Sign_symptom
precluded O
higher O
doses O
. O
Pharmacokinetic B-Diagnostic_procedure
analysis I-Diagnostic_procedure
was O
not O
undertaken O
in O
this O
patient O
. O
After B-Date
1 I-Date
month I-Date
there O
was O
a O
partial B-Diagnostic_procedure
radiographic I-Diagnostic_procedure
response I-Diagnostic_procedure
of O
LM B-Disease_disorder
on O
brain B-Biological_structure
MRI B-Diagnostic_procedure
( O
Fig. O
2b O
) O
and O
after B-Date
2 I-Date
months I-Date
in O
the O
cauda B-Biological_structure
equina I-Biological_structure
( O
not O
shown O
) O
. O
However O
, O
hydrocephalus B-Disease_disorder
and O
persistent B-Detailed_description
symptoms B-Sign_symptom
referable O
to O
increased B-Lab_value
intracranial B-Diagnostic_procedure
pressure I-Diagnostic_procedure
led O
to O
a O
VP B-Therapeutic_procedure
shunt I-Therapeutic_procedure
and O
whole-brain B-Biological_structure
radiation B-Therapeutic_procedure
therapy I-Therapeutic_procedure
, O
after O
which O
she O
resumed O
treatment O
with O
1500 O
mg O
weekly O
erlotinib O
. O
One B-Date
month I-Date
later I-Date
, O
progressive B-Detailed_description
intra-thoracic B-Disease_disorder
disease I-Disease_disorder
led O
to O
initiation O
of O
cetixumab O
and O
erlotinib O
was O
continued O
but O
changed O
to O
low O
dose O
( O
100 O
mg O
) O
daily O
. O
She O
survived B-Sign_symptom
14 B-Date
months I-Date
following I-Date
the I-Date
diagnosis I-Date
of I-Date
CNS I-Date
disease I-Date
. O
A O
33 B-Age
- I-Age
year I-Age
old I-Age
woman B-Sex
presented B-Clinical_event
to O
our O
cardiology B-Nonbiological_location
service I-Nonbiological_location
with O
signs O
and O
symptoms O
of O
congestive B-Disease_disorder
heart I-Disease_disorder
failure I-Disease_disorder
. O
Her O
medical O
history O
was O
unremarkable B-Detailed_description
, O
however O
a O
year O
ago O
and O
soon O
after O
her O
third O
child O
delivery O
, O
she O
had O
been O
admitted B-Clinical_event
in O
another O
hospital B-Nonbiological_location
for O
acute B-Disease_disorder
pulmonary I-Disease_disorder
oedema I-Disease_disorder
after O
labor O
. O
Cor B-Disease_disorder
triatriatum I-Disease_disorder
with O
obstructive O
behavior O
causing O
pulmonary B-Sign_symptom
hypertension I-Sign_symptom
had O
bee O
diagnosed B-Clinical_event
, O
while O
the O
left B-Biological_structure
ventricle I-Biological_structure
was O
structurally B-Diagnostic_procedure
and O
functionally B-Diagnostic_procedure
intact B-Lab_value
. O
The O
patient O
at O
that O
time O
denied O
surgey B-Clinical_event
and O
had O
been O
discharged B-Clinical_event
on O
medical B-Detailed_description
therapy B-Therapeutic_procedure
. O
At O
present O
admission O
the O
patient O
presented B-Clinical_event
with O
NYHA B-Diagnostic_procedure
functional I-Diagnostic_procedure
class I-Diagnostic_procedure
III B-Lab_value
, O
symptoms O
of O
heart B-Sign_symptom
failure I-Sign_symptom
and I-Sign_symptom
palpittions I-Sign_symptom
as O
a O
result O
of O
persistent B-Sign_symptom
atrial I-Sign_symptom
flutter I-Sign_symptom
. O
On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
a O
loud B-Sign_symptom
pulmonary I-Sign_symptom
component I-Sign_symptom
of I-Sign_symptom
the I-Sign_symptom
2nd I-Sign_symptom
heart I-Sign_symptom
sound I-Sign_symptom
and O
a O
diastolic B-Detailed_description
murmur B-Sign_symptom
was O
heard O
in O
the O
mitral B-Biological_structure
area I-Biological_structure
. O
Signs O
of O
right-sided B-Detailed_description
heart B-Disease_disorder
failure I-Disease_disorder
were O
absent O
. O
A O
transthoracic B-Diagnostic_procedure
echocardiography I-Diagnostic_procedure
revealed O
a O
moderately B-Severity
dilated B-Sign_symptom
left B-Biological_structure
ventricle I-Biological_structure
( O
LV B-Biological_structure
) O
, O
globally B-Detailed_description
hypokinetic B-Disease_disorder
, O
with O
severely B-Lab_value
impaired I-Lab_value
systolic B-Diagnostic_procedure
function I-Diagnostic_procedure
( O
EF B-Diagnostic_procedure
estimated O
≥ O
30 B-Lab_value
% I-Lab_value
) O
. O
Left B-Biological_structure
atrium I-Biological_structure
( O
LA B-Biological_structure
) O
was O
dilated B-Sign_symptom
, O
with O
a O
mobile B-Detailed_description
, I-Detailed_description
membrane-like I-Detailed_description
echogenic B-Sign_symptom
structure I-Sign_symptom
into O
it O
. O
Transesophageal B-Diagnostic_procedure
echocardiogram I-Diagnostic_procedure
( O
TEE B-Diagnostic_procedure
) O
documented O
a O
fibromuscular B-Sign_symptom
membrane I-Sign_symptom
across O
the O
LA O
, O
dividing O
it O
into O
two O
compartments B-Sign_symptom
, O
a O
proximal B-Detailed_description
one I-Detailed_description
receiving I-Detailed_description
the I-Detailed_description
pulmonary I-Detailed_description
venous I-Detailed_description
flow I-Detailed_description
and O
a O
distal B-Detailed_description
one I-Detailed_description
containing O
the O
left B-Biological_structure
atrial I-Biological_structure
appendage I-Biological_structure
( O
LAA B-Biological_structure
) O
. O
The O
two O
chambers O
communicated O
via O
a O
non-restrictive B-Detailed_description
orifice B-Biological_structure
, O
but O
the O
membrane B-Biological_structure
prolapsed B-Sign_symptom
towards O
the O
mitral B-Biological_structure
valve I-Biological_structure
inflow O
causing O
severe B-Severity
obstruction B-Sign_symptom
. O
Mitral B-Biological_structure
valve I-Biological_structure
appeared B-Diagnostic_procedure
normal B-Lab_value
, O
with O
mild B-Severity
regurgitation B-Sign_symptom
. O
Patent B-Disease_disorder
foramen I-Disease_disorder
ovale I-Disease_disorder
( O
PFO B-Disease_disorder
) O
, O
atrial B-Disease_disorder
septal I-Disease_disorder
defect I-Disease_disorder
( O
ASD B-Disease_disorder
) O
and O
anomalous B-Sign_symptom
venous B-Biological_structure
connections I-Biological_structure
were O
ruled O
out O
and O
the O
diagnosis O
of O
cor B-Disease_disorder
triatriatum I-Disease_disorder
was O
reconfirmed O
. O
Magnetic B-Diagnostic_procedure
resonance I-Diagnostic_procedure
imaging I-Diagnostic_procedure
( O
MRI B-Diagnostic_procedure
) O
of O
the O
heart O
also O
revealed O
the O
fibromuscular B-Sign_symptom
septum I-Sign_symptom
into O
the O
left B-Biological_structure
atrium I-Biological_structure
and O
the O
low B-Lab_value
left B-Diagnostic_procedure
ventricular I-Diagnostic_procedure
ejection I-Diagnostic_procedure
fraction I-Diagnostic_procedure
[ O
( O
LVEF B-Diagnostic_procedure
) O
30 B-Lab_value
% I-Lab_value
, O
cardiac B-Diagnostic_procedure
index I-Diagnostic_procedure
1,6 B-Lab_value
L/min/m2 I-Lab_value
, O
cardiac B-Diagnostic_procedure
output I-Diagnostic_procedure
2,7 B-Lab_value
L/min I-Lab_value
] O
( O
figure O
1 O
) O
. O
Coronary B-Diagnostic_procedure
angiography I-Diagnostic_procedure
showed O
normal B-Lab_value
coronary B-Biological_structure
arteries I-Biological_structure
. O
With O
these O
findings O
the O
patient O
was O
scheduled B-Clinical_event
for O
surgery B-Therapeutic_procedure
. O
Anesthetic O
induction O
was O
achieved O
with O
standard O
technique O
including O
administration O
of O
sodium O
pentothal O
, O
sevofluorane O
, O
fentanyl O
and O
muscle O
relaxant O
. O
Invasive B-Diagnostic_procedure
monitoring I-Diagnostic_procedure
included O
the O
use O
of O
right B-Diagnostic_procedure
radial I-Diagnostic_procedure
arterial I-Diagnostic_procedure
lines I-Diagnostic_procedure
, O
a O
pulmonary B-Diagnostic_procedure
artery I-Diagnostic_procedure
catheter I-Diagnostic_procedure
and O
a O
foley B-Diagnostic_procedure
catheter I-Diagnostic_procedure
with O
temperature B-Diagnostic_procedure
probe I-Diagnostic_procedure
to O
measure O
bladder B-Diagnostic_procedure
temperature I-Diagnostic_procedure
as O
an O
indicator O
of O
core B-Diagnostic_procedure
body I-Diagnostic_procedure
temperature I-Diagnostic_procedure
. O
Transesophageal B-Diagnostic_procedure
echocardiography I-Diagnostic_procedure
( O
TEE B-Diagnostic_procedure
) O
was O
also O
instituted O
. O
Surgery O
was O
performed O
through O
a O
median B-Therapeutic_procedure
sternotomy I-Therapeutic_procedure
. O
Connection O
to O
cardiopulmonary B-Therapeutic_procedure
bypass I-Therapeutic_procedure
( O
CPB B-Therapeutic_procedure
) O
was O
achieved O
by O
standard O
ascending B-Biological_structure
aorta I-Biological_structure
and O
bicaval B-Biological_structure
cannulation B-Therapeutic_procedure
. O
Mildly B-Severity
hypothermic B-Sign_symptom
( O
32 B-Lab_value
°C I-Lab_value
) O
CPB B-Therapeutic_procedure
was O
established O
. O
Cold B-Detailed_description
blood I-Detailed_description
cardioplegia B-Therapeutic_procedure
was O
administered O
in O
an O
antegrade B-Detailed_description
fashion O
through O
the O
aortic B-Biological_structure
root I-Biological_structure
after O
clamping B-Therapeutic_procedure
the O
aorta B-Biological_structure
. O
The O
interatrial B-Biological_structure
groove I-Biological_structure
was O
developed O
and O
the O
common B-Biological_structure
pulmonary I-Biological_structure
venous I-Biological_structure
chamber I-Biological_structure
of I-Biological_structure
the I-Biological_structure
left I-Biological_structure
atrium I-Biological_structure
was O
opened B-Therapeutic_procedure
through O
a O
vertical B-Detailed_description
incision I-Detailed_description
anterior B-Biological_structure
to I-Biological_structure
the I-Biological_structure
right I-Biological_structure
pulmonary I-Biological_structure
veins I-Biological_structure
, O
exactly O
as O
for O
mitral B-Therapeutic_procedure
valve I-Therapeutic_procedure
surgery I-Therapeutic_procedure
. O
After O
insertion O
of O
a O
self-retaining B-Detailed_description
retractor B-Therapeutic_procedure
to O
facilitate O
exposure B-Therapeutic_procedure
, O
the O
diaphragm B-Biological_structure
was O
exposed B-Therapeutic_procedure
and O
the O
central B-Detailed_description
hole B-Sign_symptom
in O
it O
was O
identified O
. O
A O
preliminary B-Detailed_description
incision B-Therapeutic_procedure
out O
from O
the O
hole B-Sign_symptom
improved O
exposure B-Therapeutic_procedure
for O
the O
definitive B-Detailed_description
excision B-Therapeutic_procedure
. O
Orifices B-Biological_structure
of O
the O
pulmonary B-Biological_structure
veins I-Biological_structure
on O
both O
sides O
were O
located B-Diagnostic_procedure
. O
Position O
of O
the O
atrial B-Biological_structure
septum I-Biological_structure
was O
also O
identified B-Diagnostic_procedure
by O
a O
small O
opening B-Therapeutic_procedure
in O
the O
right B-Biological_structure
atrium I-Biological_structure
and O
by O
inserting O
a O
curved O
clamp O
to O
displace B-Therapeutic_procedure
the O
septum B-Biological_structure
into O
the O
common B-Biological_structure
pulmonary I-Biological_structure
venous I-Biological_structure
chamber I-Biological_structure
of O
the O
left B-Biological_structure
atrium I-Biological_structure
. O
There O
was O
no O
atrial B-Disease_disorder
septal I-Disease_disorder
defect I-Disease_disorder
or O
patent B-Disease_disorder
foramen I-Disease_disorder
ovale I-Disease_disorder
. O
The O
diaphragm B-Biological_structure
was O
then O
easily O
completely B-Detailed_description
excised B-Therapeutic_procedure
exposing B-Therapeutic_procedure
the O
mitral B-Biological_structure
valve I-Biological_structure
( O
figure O
2 O
) O
. O
The O
left B-Biological_structure
atrial I-Biological_structure
appendage I-Biological_structure
was O
closed B-Therapeutic_procedure
from O
inside O
the O
left B-Biological_structure
atrium I-Biological_structure
using O
a O
running B-Detailed_description
3-0 I-Detailed_description
polypropylene I-Detailed_description
suture I-Detailed_description
to O
prevent O
future O
thrombus B-Sign_symptom
formation I-Sign_symptom
. O
The O
atriotomy B-Therapeutic_procedure
incisions I-Therapeutic_procedure
were O
closed B-Therapeutic_procedure
, O
the O
heart B-Biological_structure
having O
been O
filled O
with O
blood B-Biological_structure
before O
the O
last O
few O
sutures B-Therapeutic_procedure
were O
placed O
. O
The O
patient O
was O
rewarmed B-Therapeutic_procedure
, O
the O
aortic B-Biological_structure
cross-clamp B-Therapeutic_procedure
was O
removed O
and O
additional O
de-airing B-Therapeutic_procedure
was O
carried O
out O
in O
the O
usual O
manner O
. O
CPB B-Therapeutic_procedure
was O
terminated O
with O
minimal B-Detailed_description
inotropic O
support O
, O
involving O
milrinone O
and O
levophed O
with O
good B-Lab_value
hemodynamics B-Diagnostic_procedure
. O
The O
postoperative B-Diagnostic_procedure
course I-Diagnostic_procedure
was O
uneventful B-Lab_value
and O
the O
patient O
was O
extubated B-Therapeutic_procedure
after O
12 O
hours O
and O
discharged B-Clinical_event
from O
the O
hospital O
on O
the O
fifth B-Date
postoperative I-Date
day I-Date
. O
At O
3 B-Date
months I-Date
follow-up B-Clinical_event
, O
the O
patient O
was O
asymptomatic O
( O
NYHA B-Diagnostic_procedure
class I-Diagnostic_procedure
I B-Lab_value
) O
, O
in O
sinus B-Lab_value
rhythm B-Diagnostic_procedure
. O
TTE B-Diagnostic_procedure
and O
MRI B-Diagnostic_procedure
revealed O
a O
mildly B-Severity
dilated B-Sign_symptom
LV B-Biological_structure
with O
great O
improvement B-Lab_value
in O
systolic B-Diagnostic_procedure
function I-Diagnostic_procedure
and O
an O
estimated O
LVEF B-Diagnostic_procedure
of O
50 B-Lab_value
% I-Lab_value
. O
A O
59-year-old B-Age
man B-Sex
was O
referred B-Clinical_event
to O
the O
general B-Nonbiological_location
surgery I-Nonbiological_location
department I-Nonbiological_location
of O
our O
hospital B-Nonbiological_location
for O
a O
one-month O
history O
of O
progressive B-Detailed_description
dysphagia B-Sign_symptom
for O
solids B-Detailed_description
, O
which O
was O
not O
associated O
with O
malnutrition B-Disease_disorder
or O
significant O
weight B-Sign_symptom
loss I-Sign_symptom
. O
The O
patient O
had O
recently O
undergone O
esophagogastroduodenoscopy B-Diagnostic_procedure
in O
another B-Nonbiological_location
hospital I-Nonbiological_location
, O
which O
revealed O
a O
bleeding B-Detailed_description
, O
ulcerative B-Detailed_description
lesion B-Sign_symptom
in O
the O
middle B-Detailed_description
third I-Detailed_description
of O
the O
esophagus B-Biological_structure
, O
but O
no O
biopsy B-Diagnostic_procedure
had O
been O
collected O
. O
The O
medical O
past O
history O
included O
COPD B-Disease_disorder
diagnosed O
in O
1999 B-Date
and O
a O
myocardial B-Disease_disorder
infarction I-Disease_disorder
in O
2002 B-Date
. O
The O
patient O
had O
smoked O
approximately O
25 B-Detailed_description
cigarettes I-Detailed_description
per I-Detailed_description
day I-Detailed_description
for O
several O
years O
. O
Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
unremarkable B-Lab_value
. O
Computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
of O
the O
chest B-Biological_structure
and O
abdomen B-Biological_structure
revealed O
stenosis B-Sign_symptom
involving O
a O
5-cm O
segment B-Detailed_description
of I-Detailed_description
the I-Detailed_description
middle I-Detailed_description
third I-Detailed_description
of O
the O
esophagus B-Biological_structure
with O
no O
other O
lesions B-Sign_symptom
in O
the O
thoracic B-Biological_structure
or I-Biological_structure
abdominal I-Biological_structure
organs I-Biological_structure
. O
Barium B-Diagnostic_procedure
studies I-Diagnostic_procedure
disclosed O
a O
swelling B-Sign_symptom
in O
the O
esophageal B-Biological_structure
wall I-Biological_structure
7 O
cm O
above B-Biological_structure
the I-Biological_structure
cardia I-Biological_structure
with O
an O
ulcerative B-Detailed_description
pattern I-Detailed_description
, O
which O
reduced B-Lab_value
the O
diameter B-Diagnostic_procedure
of O
the O
lumen B-Biological_structure
to O
5 B-Lab_value
mm I-Lab_value
. O
An O
endoscopic B-Detailed_description
biopsy B-Diagnostic_procedure
of O
the O
oesophageal B-Biological_structure
mass B-Sign_symptom
demonstrated O
poorly B-Detailed_description
differentiated I-Detailed_description
( O
G3 B-Lab_value
) O
squamous B-Disease_disorder
cell I-Disease_disorder
carcinoma I-Disease_disorder
. O
Mid-distal B-Detailed_description
esophagectomy B-Therapeutic_procedure
was O
performed O
with O
oesophagogastric B-Therapeutic_procedure
anastomosis I-Therapeutic_procedure
and O
gastric B-Biological_structure
tube I-Biological_structure
reconstruction B-Therapeutic_procedure
. O
Pathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
the O
surgical O
specimen O
confirmed O
the O
biopsy B-Diagnostic_procedure
diagnosis O
of O
poorly B-Detailed_description
differentiated I-Detailed_description
( O
G3 B-Lab_value
) O
SCC B-Disease_disorder
. O
The O
tumor O
, O
which O
measured O
3 O
cm O
of O
length O
, O
had O
infiltrated B-Sign_symptom
the O
oesophageal B-Biological_structure
wall I-Biological_structure
and O
the O
surrounding O
paraesophageal B-Biological_structure
fat I-Biological_structure
. O
Surgical B-Diagnostic_procedure
margins I-Diagnostic_procedure
were O
tumor-free B-Lab_value
, O
as O
the O
seven O
perigastric B-Biological_structure
limph-nodes I-Biological_structure
dissected B-Diagnostic_procedure
( O
pT3 B-Lab_value
N0 I-Lab_value
) O
. O
The O
postoperative B-Diagnostic_procedure
period I-Diagnostic_procedure
was O
quite O
unremarkable B-Lab_value
, O
and O
a O
contrast B-Detailed_description
enhanced I-Detailed_description
x-ray B-Diagnostic_procedure
obtained O
on O
the O
9th B-Date
POD I-Date
showed O
normal B-Lab_value
esophageal B-Diagnostic_procedure
and I-Diagnostic_procedure
gastric I-Diagnostic_procedure
transit I-Diagnostic_procedure
. O
On O
the O
14th B-Date
POD I-Date
, O
the O
patient O
was O
discharged B-Clinical_event
with O
an O
oncology B-Nonbiological_location
referral B-Clinical_event
for O
routine O
medical O
follow-up B-Clinical_event
. O
Nine B-Date
months I-Date
after I-Date
the O
operation O
, O
CT B-Diagnostic_procedure
and O
esophagogastroduodenoscopy B-Diagnostic_procedure
were O
repeated O
. O
The O
imaging B-Diagnostic_procedure
study I-Diagnostic_procedure
revealed O
mild B-Severity
splenomegaly B-Sign_symptom
with O
multiple O
nonspecific O
nodules B-Sign_symptom
within O
the O
organ B-Biological_structure
( O
Figure O
1 O
) O
. O
The O
patient O
was O
virtually O
asymptomatic B-Sign_symptom
with O
the O
exception O
of O
a O
vague O
sensation O
of O
mild B-Severity
discomfort B-Sign_symptom
in O
the O
left B-Biological_structure
upper I-Biological_structure
quadrant I-Biological_structure
of I-Biological_structure
the I-Biological_structure
abdomen I-Biological_structure
. O
FNAC B-Diagnostic_procedure
of O
the O
spleen B-Biological_structure
revealed O
a O
pattern O
of O
numerous O
inflammatory B-Sign_symptom
cells I-Sign_symptom
admixed I-Sign_symptom
with I-Sign_symptom
large I-Sign_symptom
cells I-Sign_symptom
displaying O
immunohistochemical O
positivity B-Lab_value
for O
several O
cytokeratins B-Diagnostic_procedure
( O
Figure O
2 O
) O
. O
The O
specimen O
was O
Gram B-Diagnostic_procedure
stain-negative I-Diagnostic_procedure
. O
A O
bone-marrow B-Biological_structure
biopsy B-Diagnostic_procedure
was O
negative B-Lab_value
for O
metastatic B-Diagnostic_procedure
involvement I-Diagnostic_procedure
. O
The O
diagnosis O
was O
isolated O
metastases B-Disease_disorder
of O
the O
spleen B-Biological_structure
with O
inflammatory B-Detailed_description
and O
necrotic B-Detailed_description
alterations B-Sign_symptom
. O
The O
patient O
was O
referred B-Clinical_event
to O
our O
centre B-Nonbiological_location
for O
splenectomy B-Therapeutic_procedure
, O
which O
was O
performed O
as O
a O
routine O
procedure O
to O
role O
out O
, O
also O
, O
a O
spontaneous B-Detailed_description
rupture B-Sign_symptom
of O
the O
spleen B-Biological_structure
. O
On O
12th B-Date
December I-Date
2007 I-Date
, O
the O
patient O
had O
transabdominal B-Detailed_description
total B-Detailed_description
splenectomy B-Therapeutic_procedure
with O
splenic B-Biological_structure
and O
celiac B-Biological_structure
artery I-Biological_structure
lymph B-Therapeutic_procedure
node I-Therapeutic_procedure
dissection I-Therapeutic_procedure
. O
The O
postoperative B-Diagnostic_procedure
course I-Diagnostic_procedure
was O
uneventful B-Lab_value
. O
On O
the O
7th B-Date
postoperative I-Date
day I-Date
, O
Doppler B-Detailed_description
ultrasonography B-Diagnostic_procedure
revealed O
portal-tree B-Detailed_description
patency B-Sign_symptom
with O
no O
signs O
of O
thrombosis B-Disease_disorder
. O
Ten B-Date
days I-Date
later I-Date
, O
the O
patient O
was O
discharged B-Clinical_event
with O
a O
stable B-Lab_value
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
( O
780,000 B-Lab_value
/ I-Lab_value
mm3 I-Lab_value
) O
, O
Hb B-Diagnostic_procedure
10.9 B-Lab_value
g/dL I-Lab_value
, O
and O
a O
WBC B-Diagnostic_procedure
count I-Diagnostic_procedure
of O
16,500 B-Lab_value
/ I-Lab_value
mm3 I-Lab_value
. O
Pathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
of O
the O
spleen B-Biological_structure
described O
multiple O
nodules B-Sign_symptom
containing O
medium B-Detailed_description
to I-Detailed_description
large-sized I-Detailed_description
cells I-Detailed_description
, O
some B-Detailed_description
of I-Detailed_description
which I-Detailed_description
were I-Detailed_description
keratinized I-Detailed_description
. O
The O
nodules B-Sign_symptom
were O
mostly O
solid O
with O
areas B-Detailed_description
of I-Detailed_description
central I-Detailed_description
necrosis I-Detailed_description
( O
Figure O
3 O
) O
. O
The O
findings O
were O
consistent O
with O
metastases B-Disease_disorder
of O
SCC B-Disease_disorder
. O
Thereafter O
, O
the O
patient O
was O
referred B-Clinical_event
to O
the O
oncology B-Nonbiological_location
department I-Nonbiological_location
of O
our O
hospital B-Nonbiological_location
, O
where O
he O
received O
two O
3-day O
cycles O
( O
separated B-Detailed_description
by I-Detailed_description
a I-Detailed_description
3-week I-Detailed_description
interval I-Detailed_description
) O
of O
systemic B-Detailed_description
chemotherapy O
based O
on O
5-fluorouracil O
( O
800 O
mg/day O
IV O
) O
and O
cisplatin O
( O
20 O
mg/day O
) O
. O
Three B-Date
months I-Date
after I-Date
the O
splenectomy B-Therapeutic_procedure
, O
multiple O
liver B-Biological_structure
metastases B-Disease_disorder
were O
seen O
on O
the O
CT B-Diagnostic_procedure
scan O
, O
and O
cutaneous B-Biological_structure
metastases B-Disease_disorder
were O
also O
present O
. O
The O
patient O
died O
9 B-Date
months I-Date
later I-Date
. O
This O
16-year-old B-Age
boy B-Sex
was O
the O
first O
child O
to O
non-consanguineous O
parents O
. O
His O
parents O
and O
two O
younger O
siblings O
were O
healthy O
. O
He O
was O
well O
until O
starting O
school O
at O
7 B-Date
years I-Date
of I-Date
age I-Date
when O
he O
was O
found O
to O
be O
short B-Sign_symptom
in I-Sign_symptom
height I-Sign_symptom
, O
slightly B-Sign_symptom
myopic I-Sign_symptom
, O
astigmatic B-Sign_symptom
and O
to O
have O
subnormal B-Sign_symptom
visual I-Sign_symptom
acuity I-Sign_symptom
. O
Endocrinological B-Diagnostic_procedure
investigations I-Diagnostic_procedure
were O
performed O
that O
initially O
revealed O
borderline B-Lab_value
values I-Lab_value
for O
growth B-Sign_symptom
hormone I-Sign_symptom
( I-Sign_symptom
GH I-Sign_symptom
) I-Sign_symptom
deficiency I-Sign_symptom
and O
he O
was O
therefore O
treated B-Clinical_event
for O
a O
period O
with O
GH O
without O
any O
beneficiary B-Sign_symptom
effect I-Sign_symptom
on I-Sign_symptom
his I-Sign_symptom
growth I-Sign_symptom
. O
At O
age O
16 B-Date
years I-Date
, O
height B-Sign_symptom
and I-Sign_symptom
weight I-Sign_symptom
was I-Sign_symptom
− I-Sign_symptom
3 I-Sign_symptom
SD I-Sign_symptom
below I-Sign_symptom
the I-Sign_symptom
mean I-Sign_symptom
compared O
with O
a O
standardized O
Swedish O
growth O
chart O
. O
Ophthalmological B-Diagnostic_procedure
investigations I-Diagnostic_procedure
at O
10 B-Date
years I-Date
of I-Date
age I-Date
showed O
pigmentary B-Sign_symptom
retinopathy I-Sign_symptom
and O
optic B-Sign_symptom
atrophy I-Sign_symptom
. O
An O
electroretinogram B-Diagnostic_procedure
was O
performed O
and O
showed O
a O
severe B-Severity
rod B-Sign_symptom
cone I-Sign_symptom
dystrophy I-Sign_symptom
. O
He O
had O
decreased B-Lab_value
visual B-Sign_symptom
acuity I-Sign_symptom
, O
visual B-Sign_symptom
fields I-Sign_symptom
, O
color B-Sign_symptom
vision I-Sign_symptom
, O
and O
dark B-Sign_symptom
adaption I-Sign_symptom
. O
Nystagmus B-Sign_symptom
has O
been O
noted O
since O
14 B-Date
years I-Date
of I-Date
age I-Date
. O
A B-Date
year I-Date
later I-Date
, O
photophobia B-Sign_symptom
and O
bilateral B-Sign_symptom
cataracts I-Sign_symptom
were O
developed O
. O
The O
cataracts B-Therapeutic_procedure
were I-Therapeutic_procedure
operated I-Therapeutic_procedure
on I-Therapeutic_procedure
at O
16 B-Date
years I-Date
of I-Date
age I-Date
. O
He O
is O
now B-Date
blind B-Sign_symptom
. O
At O
14 B-Date
years I-Date
of I-Date
age I-Date
, O
he O
was O
referred O
for O
neurological B-Diagnostic_procedure
investigations I-Diagnostic_procedure
. O
A O
clinical B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
mild B-Severity
ataxia B-Sign_symptom
with I-Sign_symptom
tremor I-Sign_symptom
, O
dysmetria B-Sign_symptom
and O
gait B-Sign_symptom
instability I-Sign_symptom
together O
with O
mild B-Severity
to I-Severity
moderate I-Severity
muscle B-Sign_symptom
weakness I-Sign_symptom
, O
weak B-Severity
to I-Severity
absent I-Severity
tendon B-Sign_symptom
reflexes I-Sign_symptom
in O
the O
lower B-Biological_structure
extremities I-Biological_structure
, O
and O
exercise B-Sign_symptom
intolerance I-Sign_symptom
. O
Audiometric B-Diagnostic_procedure
investigations I-Diagnostic_procedure
revealed O
a O
mild B-Severity
bilateral B-Detailed_description
sensorineural B-Sign_symptom
hearing I-Sign_symptom
impairment I-Sign_symptom
. O
At O
15 B-Date
years I-Date
of I-Date
age I-Date
, O
he O
had O
an O
unprovoked B-Detailed_description
epileptic B-Sign_symptom
seizure I-Sign_symptom
and O
he O
has O
since O
then O
been O
treated B-Clinical_event
with O
levetiracetam O
. O
Decreased B-Sign_symptom
renal I-Sign_symptom
function I-Sign_symptom
was O
identified O
at O
15 B-Date
years I-Date
of I-Date
age I-Date
, O
with O
increased B-Lab_value
serum B-Diagnostic_procedure
creatinine I-Diagnostic_procedure
to O
145 B-Lab_value
μmol/l I-Lab_value
( O
reference O
interval O
30 O
– O
90 O
μmol/l O
) O
, O
proteinuria B-Sign_symptom
with O
urine B-Diagnostic_procedure
albumine I-Diagnostic_procedure
at O
244 B-Lab_value
– I-Lab_value
538 I-Lab_value
mg/l I-Lab_value
( O
reference O
interval O
< O
20 O
mg/l O
) O
, O
and O
urine B-Diagnostic_procedure
albumine/creatinine I-Diagnostic_procedure
ratio O
at O
44 B-Lab_value
– I-Lab_value
59 I-Lab_value
g/mol I-Lab_value
( O
reference O
interval O
< O
3 O
g/mol O
) O
. O
A O
renal B-Biological_structure
scintigraphy B-Diagnostic_procedure
demonstrated O
reduced B-Sign_symptom
kidney I-Sign_symptom
size I-Sign_symptom
. O
Cr51-EDTA B-Diagnostic_procedure
clearance I-Diagnostic_procedure
showed O
a O
decreased B-Lab_value
glomerular B-Diagnostic_procedure
filtration I-Diagnostic_procedure
rate I-Diagnostic_procedure
of O
42 B-Lab_value
% I-Lab_value
of I-Lab_value
normal I-Lab_value
. I-Lab_value
The O
filtration O
rate O
decreased B-Lab_value
over O
time O
to O
29 B-Lab_value
% I-Lab_value
of I-Lab_value
normal I-Lab_value
at O
16 B-Date
years I-Date
of I-Date
age I-Date
. O
Since O
14 B-Date
years I-Date
of I-Date
age I-Date
, O
cardiac B-Diagnostic_procedure
investigations I-Diagnostic_procedure
have O
demonstrated O
hypertrophy B-Sign_symptom
of O
the O
walls B-Biological_structure
of I-Biological_structure
the I-Biological_structure
left I-Biological_structure
ventricle I-Biological_structure
( O
+3 O
SD O
compared O
with O
normal O
) O
with O
normal B-Severity
systolic B-Sign_symptom
and I-Sign_symptom
diastolic I-Sign_symptom
function I-Sign_symptom
and O
without O
obstruction B-Sign_symptom
of I-Sign_symptom
the I-Sign_symptom
outflow I-Sign_symptom
. O
Mitochondrial B-Diagnostic_procedure
investigations I-Diagnostic_procedure
were O
performed O
at O
14 B-Date
years I-Date
of I-Date
age I-Date
. O
Blood B-Diagnostic_procedure
levels I-Diagnostic_procedure
of O
lactate B-Diagnostic_procedure
and O
pyruvate B-Diagnostic_procedure
were O
1.6 B-Lab_value
and O
0.096 B-Lab_value
mmol/l I-Lab_value
, O
respectively O
, O
leading O
to O
a O
ratio B-Diagnostic_procedure
of O
33 B-Lab_value
( O
reference O
interval O
< O
20 O
) O
, O
while O
cerebrospinal B-Diagnostic_procedure
fluid I-Diagnostic_procedure
( O
CSF B-Diagnostic_procedure
) O
levels O
of O
lactate B-Diagnostic_procedure
and O
pyruvate B-Diagnostic_procedure
were O
3.6 B-Lab_value
and O
0.137 B-Lab_value
mmol/l I-Lab_value
, I-Lab_value
respectively O
, O
leading O
to O
a O
lactate B-Diagnostic_procedure
to I-Diagnostic_procedure
pyruvate I-Diagnostic_procedure
ratio I-Diagnostic_procedure
of O
26 B-Lab_value
. O
The O
urinary B-Diagnostic_procedure
lactate I-Diagnostic_procedure
excretion I-Diagnostic_procedure
was O
normal B-Lab_value
. O
The O
CSF B-Diagnostic_procedure
albumin I-Diagnostic_procedure
was O
increased B-Lab_value
to O
258 B-Lab_value
mg/l I-Lab_value
( O
reference O
level O
< O
225 O
mg/l O
) O
and O
he O
also O
had O
an O
increased B-Lab_value
CSF/plasma B-Diagnostic_procedure
albumin I-Diagnostic_procedure
ratio I-Diagnostic_procedure
of O
7.4 B-Lab_value
( O
reference O
level O
< O
5 O
) O
. O
The O
serum B-Diagnostic_procedure
acyl I-Diagnostic_procedure
carnitine I-Diagnostic_procedure
profile I-Diagnostic_procedure
and O
muscle B-Diagnostic_procedure
carnitine I-Diagnostic_procedure
levels I-Diagnostic_procedure
were O
normal B-Lab_value
. O
The O
serum B-Diagnostic_procedure
creatine I-Diagnostic_procedure
kinase I-Diagnostic_procedure
activity I-Diagnostic_procedure
was O
mildly B-Lab_value
increased I-Lab_value
to O
5.4 B-Lab_value
μkat/l I-Lab_value
( O
reference O
interval O
< O
3.5 O
μkat/l O
) O
. O
A O
60-year-old B-Age
Caucasian O
woman B-Sex
with O
no O
significant O
medical O
history O
developed O
exercise B-Sign_symptom
intolerance I-Sign_symptom
, O
fatigue B-Sign_symptom
and O
shortness B-Sign_symptom
of I-Sign_symptom
breath I-Sign_symptom
on O
exertion B-Detailed_description
over O
the O
several O
months O
prior O
to O
her O
presentation B-Clinical_event
to O
our O
outpatient B-Nonbiological_location
clinic I-Nonbiological_location
. O
At O
the O
time O
of O
presentation O
, O
she O
also O
reported O
of O
dry B-Detailed_description
cough B-Sign_symptom
, O
orthopnea B-Sign_symptom
, O
paroxysmal B-Detailed_description
nocturnal B-Detailed_description
dyspnoea B-Sign_symptom
, O
generalised B-Detailed_description
weakness B-Sign_symptom
and O
intermittent B-Detailed_description
numbness B-Sign_symptom
of O
her O
hands B-Biological_structure
and O
feet B-Biological_structure
. O
Social O
history O
was O
negative O
for O
smoking O
, O
alcohol O
or O
illicit O
drugs O
. O
Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
unremarkable B-Lab_value
, O
except O
for O
jugular B-Biological_structure
venous I-Biological_structure
distension B-Sign_symptom
, O
audible O
S1 B-Sign_symptom
and I-Sign_symptom
S2 I-Sign_symptom
sounds I-Sign_symptom
, O
bilateral B-Detailed_description
crackles B-Sign_symptom
on O
lung B-Diagnostic_procedure
auscultation I-Diagnostic_procedure
and O
bilateral B-Detailed_description
pitting B-Detailed_description
oedema B-Sign_symptom
. O
Chest B-Biological_structure
X-ray B-Diagnostic_procedure
showed O
cardiomegaly B-Sign_symptom
, O
pulmonary B-Sign_symptom
oedema I-Sign_symptom
and O
small-sized B-Severity
bilateral B-Detailed_description
pleural B-Sign_symptom
effusions I-Sign_symptom
. O
A O
12-lead B-Detailed_description
ECG B-Diagnostic_procedure
demonstrated O
normal B-Lab_value
sinus B-Diagnostic_procedure
rhythm I-Diagnostic_procedure
, O
low-voltage B-Sign_symptom
complexes I-Sign_symptom
and O
extreme B-Severity
right-axis B-Sign_symptom
deviation I-Sign_symptom
( O
figure O
1 O
) O
. O
Transthoracic B-Diagnostic_procedure
echocardiogram I-Diagnostic_procedure
( O
TTE B-Diagnostic_procedure
) O
demonstrated O
asymmetric B-Detailed_description
biventricular B-Biological_structure
hypertrophy B-Sign_symptom
with O
preserved B-Lab_value
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
of O
60 B-Lab_value
% I-Lab_value
, O
elevated B-Lab_value
right-ventricular B-Biological_structure
systolic B-Diagnostic_procedure
pressure I-Diagnostic_procedure
of O
36 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
and O
abnormal B-Lab_value
myocardial B-Diagnostic_procedure
texture I-Diagnostic_procedure
, O
described O
as O
‘ O
granular O
sparkling O
’ O
( O
figure O
2 O
) O
. O
Coronary B-Biological_structure
CT B-Diagnostic_procedure
angiogram I-Diagnostic_procedure
demonstrated O
normal B-Lab_value
coronary B-Biological_structure
arteries I-Biological_structure
. O
Subsequently O
, O
cardiac B-Biological_structure
MRI B-Diagnostic_procedure
demonstrated O
early B-Detailed_description
and O
diffuse B-Detailed_description
subendocardial B-Biological_structure
delayed B-Sign_symptom
enhancement I-Sign_symptom
, O
concerning O
for O
infiltrative B-Disease_disorder
myocardial I-Disease_disorder
disease I-Disease_disorder
and O
for O
diffuse B-Detailed_description
biventricular B-Biological_structure
hypertrophy B-Sign_symptom
, O
with O
normal B-Lab_value
ejection B-Diagnostic_procedure
fraction I-Diagnostic_procedure
( O
figure O
3 O
) O
. O
The O
patient O
underwent O
right B-Detailed_description
heart B-Therapeutic_procedure
catheterisation I-Therapeutic_procedure
with O
endomyocardial B-Biological_structure
biopsy B-Diagnostic_procedure
, O
revealing O
diffuse B-Detailed_description
amyloidosis B-Disease_disorder
with O
amorphous B-Detailed_description
proteinaceous B-Sign_symptom
material I-Sign_symptom
around O
cardiac B-Biological_structure
myocytes I-Biological_structure
and O
within O
blood B-Biological_structure
vessels I-Biological_structure
, O
which O
was O
positive B-Lab_value
for O
Congo B-Diagnostic_procedure
red I-Diagnostic_procedure
stain I-Diagnostic_procedure
( O
figure O
4 O
) O
. O
Subsequent O
laboratory B-Diagnostic_procedure
evaluation I-Diagnostic_procedure
registered O
elevated B-Lab_value
, O
free B-Diagnostic_procedure
λ I-Diagnostic_procedure
light I-Diagnostic_procedure
chains I-Diagnostic_procedure
( O
86.3 B-Lab_value
mg/L I-Lab_value
( O
normal O
: O
5.7 O
– O
26.3 O
mg/L O
) O
) O
and O
positive B-Lab_value
Bence-Jones B-Diagnostic_procedure
protein I-Diagnostic_procedure
( O
0.37 B-Lab_value
g/24 I-Lab_value
h I-Lab_value
) O
in O
the O
urine B-Detailed_description
. O
Bone B-Biological_structure
marrow I-Biological_structure
biopsy B-Diagnostic_procedure
revealed O
greater B-Lab_value
than I-Lab_value
10 I-Lab_value
% I-Lab_value
infiltration B-Diagnostic_procedure
of O
CD19 B-Detailed_description
− I-Detailed_description
CD56 I-Detailed_description
+ I-Detailed_description
CD138 I-Detailed_description
+ I-Detailed_description
plasma I-Detailed_description
cells I-Detailed_description
with O
reversal B-Lab_value
of O
marrow B-Diagnostic_procedure
κ/λ I-Diagnostic_procedure
ratio I-Diagnostic_procedure
( O
< B-Lab_value
1:2 I-Lab_value
, O
normal O
: O
2:1 O
) O
, O
consistent O
with O
MM B-Disease_disorder
. O
The O
patient O
was O
eventually O
diagnosed O
with O
systemic B-Detailed_description
AL B-Detailed_description
amyloidosis B-Disease_disorder
with O
advanced B-Severity
, O
stage B-Detailed_description
III I-Detailed_description
, O
cardiac B-Biological_structure
amyloidosis B-Disease_disorder
due O
to O
underlying O
MM B-Disease_disorder
. O
Given O
her O
advanced B-Severity
cardiac B-Biological_structure
amyloidosis B-Disease_disorder
, O
the O
patient O
was O
deemed O
a O
poor O
candidate O
for O
autologous B-Therapeutic_procedure
stem-cell I-Therapeutic_procedure
transplantation I-Therapeutic_procedure
. O
The O
patient O
was O
started O
on O
systemic B-Detailed_description
chemotherapy O
with O
melphalan O
and O
dexamethasone O
. O
Despite O
receiving O
standard O
therapy O
for O
heart O
failure O
— O
including O
diuretics O
, O
β-blockers O
and O
ACE O
inhibitors O
— O
the O
patient O
's O
condition B-Diagnostic_procedure
continued O
to O
worsen B-Lab_value
and O
she O
succumbed O
to O
sudden B-Disease_disorder
cardiac I-Disease_disorder
death I-Disease_disorder
. O
A O
30-year-old B-Age
woman B-Sex
with O
a O
history O
of O
HIV O
and O
HCV O
presented B-Clinical_event
to O
the O
emergency B-Nonbiological_location
department I-Nonbiological_location
with O
a O
4-month O
history O
of O
gradual B-Detailed_description
but O
progressive B-Detailed_description
swelling B-Sign_symptom
of O
her O
lower B-Biological_structure
limbs I-Biological_structure
and O
abdomen B-Biological_structure
. O
She O
denied O
any O
chest B-Biological_structure
pain B-Sign_symptom
, O
dyspnoea B-Sign_symptom
, O
paroxysmal B-Detailed_description
nocturnal B-Detailed_description
dyspnoea B-Sign_symptom
or O
orthopnoea B-Sign_symptom
. O
Vitals B-Diagnostic_procedure
were O
stable B-Lab_value
. O
Cardiovascular B-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
remarkable O
for O
an O
elevated B-Lab_value
jugular B-Diagnostic_procedure
venous I-Diagnostic_procedure
pressure I-Diagnostic_procedure
( O
JVP B-Diagnostic_procedure
) O
of O
about O
12 B-Lab_value
cm I-Lab_value
with O
a O
pronounced B-Lab_value
‘ I-Lab_value
y I-Lab_value
’ I-Lab_value
descent I-Lab_value
. O
There O
was O
a O
prominent B-Severity
pericardial B-Sign_symptom
knock I-Sign_symptom
sound I-Sign_symptom
heard O
over O
the O
praecordium B-Biological_structure
. O
There O
was O
no O
pericardial B-Sign_symptom
rub I-Sign_symptom
or O
murmur B-Sign_symptom
. O
The O
lungs B-Biological_structure
were O
clear B-Lab_value
to O
auscultation B-Diagnostic_procedure
. O
The O
patient O
was O
markedly O
oedematous B-Sign_symptom
from O
the O
abdomen B-Biological_structure
to O
the O
lower B-Biological_structure
limbs I-Biological_structure
. O
She O
was O
admitted B-Clinical_event
for O
further O
diagnostic B-Diagnostic_procedure
work-up I-Diagnostic_procedure
and O
management B-Therapeutic_procedure
. O
She O
was O
diagnosed O
with O
HIV B-Disease_disorder
around O
May B-Date
2010 I-Date
and O
had O
been O
on O
antiretroviral O
therapy O
. O
She O
had O
not O
used O
illicit O
drugs O
for O
approximately O
5 O
– O
6 O
years O
. O
Renal B-Disease_disorder
and I-Disease_disorder
hepatic I-Disease_disorder
diseases I-Disease_disorder
were O
ruled O
out O
through O
blood B-Diagnostic_procedure
tests I-Diagnostic_procedure
and O
imaging B-Diagnostic_procedure
. O
Peritoneal B-Biological_structure
fluid I-Biological_structure
was O
negative O
for O
malignancy B-Disease_disorder
. O
Echocardiogram B-Diagnostic_procedure
showed O
a O
thickened B-Lab_value
bright B-Lab_value
pericardium B-Biological_structure
adjacent O
to O
the O
right B-Biological_structure
heart I-Biological_structure
border I-Biological_structure
( O
figure O
1 O
) O
with O
parallel B-Lab_value
separation I-Lab_value
between I-Lab_value
epicardial I-Lab_value
and I-Lab_value
pericardial I-Lab_value
echoes I-Lab_value
( O
railroad O
track O
sign O
) O
, O
septal B-Lab_value
bounce I-Lab_value
and O
lack O
of O
pericardial B-Lab_value
slide I-Lab_value
. O
Annulus B-Sign_symptom
paradoxus I-Sign_symptom
was O
demonstrated O
on O
tissue B-Biological_structure
Doppler B-Diagnostic_procedure
( O
figure O
2 O
) O
. O
Left B-Diagnostic_procedure
ventricular I-Diagnostic_procedure
ejection I-Diagnostic_procedure
fraction I-Diagnostic_procedure
was O
64 B-Lab_value
% I-Lab_value
. O
The O
right B-Biological_structure
ventricle I-Biological_structure
was O
normal B-Lab_value
in O
size B-Diagnostic_procedure
and O
function B-Diagnostic_procedure
. O
There O
was O
moderate B-Severity
tricuspid B-Sign_symptom
regurgitation I-Sign_symptom
. O
There O
was O
no O
pericardial B-Sign_symptom
effusion I-Sign_symptom
, O
but O
the O
pericardial B-Biological_structure
space I-Biological_structure
was O
remarkable O
for O
debris B-Sign_symptom
. O
Constrictive B-Disease_disorder
physiology I-Disease_disorder
was O
demonstrated O
by O
Doppler B-Diagnostic_procedure
study O
of O
tricuspid O
and O
mitral O
inflows O
( O
figure O
3 O
) O
during O
inspiration O
and O
expiration O
; O
diastolic B-Sign_symptom
flow I-Sign_symptom
reversal I-Sign_symptom
was O
also O
demonstrated O
in O
the O
hepatic B-Biological_structure
veins I-Biological_structure
during O
expiration O
. O
There O
was O
marked O
dilatation B-Sign_symptom
of O
the O
inferior B-Biological_structure
vena I-Biological_structure
cava I-Biological_structure
with O
no O
change O
during O
inspiration O
or O
expiration O
. O
CT B-Diagnostic_procedure
of O
the O
chest B-Biological_structure
revealed O
thickening B-Sign_symptom
of O
the O
pericardium B-Biological_structure
with O
no O
evidence O
of O
calcification B-Sign_symptom
. O
There O
were O
no O
lung B-Biological_structure
nodules B-Sign_symptom
. O
Bilateral B-Detailed_description
pleural B-Disease_disorder
effusions I-Disease_disorder
and O
interstitial B-Detailed_description
thickening B-Sign_symptom
were O
present O
in O
the O
lung B-Biological_structure
bases I-Biological_structure
. O
Cardiac B-Biological_structure
MRI B-Diagnostic_procedure
confirmed O
the O
presence O
of O
a O
diffusely B-Detailed_description
thickened B-Sign_symptom
pericardium B-Biological_structure
at O
5 B-Lab_value
mm I-Lab_value
. O
The O
inferior B-Biological_structure
vena I-Biological_structure
cava I-Biological_structure
and O
hepatic B-Biological_structure
veins I-Biological_structure
appeared O
plethoric B-Sign_symptom
. O
There O
was O
a O
rapid B-Lab_value
early B-Diagnostic_procedure
diastolic I-Diagnostic_procedure
filling I-Diagnostic_procedure
and O
associated O
diastolic B-Sign_symptom
septal I-Sign_symptom
bounce I-Sign_symptom
secondary O
to O
hindered B-Lab_value
late B-Diagnostic_procedure
diastolic I-Diagnostic_procedure
filling I-Diagnostic_procedure
( O
figure O
4 O
) O
. O
The O
patient O
showed O
a O
good B-Lab_value
response B-Diagnostic_procedure
to O
diuresis B-Therapeutic_procedure
. O
She O
underwent O
right B-Detailed_description
and O
left B-Detailed_description
heart B-Biological_structure
catheterisation B-Therapeutic_procedure
to O
confirm O
constrictive B-Disease_disorder
physiology I-Disease_disorder
. O
A O
45-year-old B-Age
woman B-Sex
presents B-Clinical_event
to O
her O
general B-Nonbiological_location
practitioner I-Nonbiological_location
because O
of O
left-sided B-Detailed_description
neck B-Biological_structure
and O
shoulder B-Biological_structure
pain B-Sign_symptom
. O
The O
pain B-Sign_symptom
was O
mild B-Severity
and O
non-specific B-Detailed_description
and O
the O
patient O
's O
history O
was O
unremarkable O
. O
She O
denied O
a O
history O
of O
smoking O
, O
excessive O
alcohol O
use O
and O
radiation O
exposure O
. O
Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
demonstrated O
mild B-Severity
left B-Detailed_description
sided I-Detailed_description
cervical B-Biological_structure
lymphadenopathy B-Sign_symptom
. O
Routine O
blood B-Diagnostic_procedure
tests I-Diagnostic_procedure
revealed O
borderline B-Lab_value
elevated I-Lab_value
calcium B-Diagnostic_procedure
of O
10.5 B-Lab_value
mg/dL I-Lab_value
and O
subsequent O
work B-Diagnostic_procedure
up I-Diagnostic_procedure
exhibited O
a O
markedly O
elevated B-Lab_value
parathyroid B-Diagnostic_procedure
hormone I-Diagnostic_procedure
level O
of O
286 B-Lab_value
pg/mL I-Lab_value
, O
so O
the O
patient O
was O
referred B-Clinical_event
to O
otolaryngology B-Nonbiological_location
for O
further O
evaluation O
. O
Thyroid B-Biological_structure
ultrasound B-Diagnostic_procedure
showed O
a O
hypoechoic B-Detailed_description
nodule B-Sign_symptom
in O
the O
left B-Biological_structure
lower I-Biological_structure
lobe I-Biological_structure
of I-Biological_structure
the I-Biological_structure
thyroid I-Biological_structure
. O
CT B-Diagnostic_procedure
scan O
of O
the O
neck B-Biological_structure
revealed O
a O
2 O
cm O
hypodense B-Detailed_description
nodule B-Sign_symptom
on O
the O
posterior B-Biological_structure
inferior I-Biological_structure
aspect I-Biological_structure
of I-Biological_structure
the I-Biological_structure
left I-Biological_structure
lower I-Biological_structure
thyroid I-Biological_structure
and O
sestamibi B-Diagnostic_procedure
scan O
showed O
increased B-Sign_symptom
uptake I-Sign_symptom
along O
the O
lower B-Biological_structure
pole I-Biological_structure
of I-Biological_structure
the I-Biological_structure
left I-Biological_structure
thyroid I-Biological_structure
lobe I-Biological_structure
. O
Elevated B-Lab_value
PTH B-Diagnostic_procedure
along O
with O
an O
aberrant B-Sign_symptom
parathyroid B-Biological_structure
gland I-Biological_structure
on O
imaging B-Diagnostic_procedure
suggests O
primary B-Detailed_description
hyperparathyroidism B-Disease_disorder
. O
Historically O
, O
hyperparathyroidism B-Disease_disorder
is O
associated O
with O
bone B-Disease_disorder
disease I-Disease_disorder
, O
renal B-Disease_disorder
stones I-Disease_disorder
and O
neuromuscular B-Disease_disorder
dysfunction I-Disease_disorder
, O
however O
, O
with O
the O
current O
screening B-Diagnostic_procedure
modalities I-Diagnostic_procedure
, O
most O
patients O
are O
caught O
early O
and O
often O
asymptomatic B-Sign_symptom
.3 O
Primary B-Detailed_description
hyperparathyroidism B-Disease_disorder
is O
most O
commonly O
caused O
by O
a O
parathyroid B-Biological_structure
adenoma B-Disease_disorder
. O
Infrequent O
causes O
include O
parathyroid B-Biological_structure
hyperplasia B-Disease_disorder
, O
which O
would O
affect O
all O
four O
glands O
and O
rarely O
caused O
by O
parathyroid B-Biological_structure
carcinoma B-Disease_disorder
. O
Markedly O
elevated B-Lab_value
serum B-Detailed_description
PTH B-Diagnostic_procedure
and O
calcium B-Diagnostic_procedure
levels O
leading O
to O
severe B-Severity
renal B-Biological_structure
and O
bone B-Biological_structure
manifestations B-Sign_symptom
are O
helpful O
in O
the O
diagnosis O
of O
cancer B-Disease_disorder
, O
however O
, O
it O
is O
usually O
discovered O
operatively B-Therapeutic_procedure
based O
on O
local O
invasion B-Sign_symptom
and O
metastases B-Disease_disorder
.3 O
The O
primary O
indication O
for O
parathyroidectomy B-Therapeutic_procedure
, O
historically O
, O
is O
for O
symptomatic O
patients O
. O
Currently O
, O
since O
most O
patients O
are O
caught O
earlier O
, O
there O
are O
newer O
indications O
for O
surgery B-Therapeutic_procedure
. O
These O
include O
an O
asymptomatic O
patient O
with O
any O
of O
the O
following O
: O
glomerular B-Diagnostic_procedure
filtration I-Diagnostic_procedure
rate I-Diagnostic_procedure
< O
60 O
mL/min O
, O
bone B-Diagnostic_procedure
density I-Diagnostic_procedure
T-score I-Diagnostic_procedure
< O
− O
2.5 O
at O
any O
site O
and/or O
previous O
fractures B-Disease_disorder
, O
age O
< O
50 O
, O
and O
serum B-Detailed_description
calcium B-Diagnostic_procedure
1.0 O
ng/dL O
above O
the O
upper O
limit O
of O
normal O
.3 O
This O
patient O
presented O
with O
pain B-Sign_symptom
, O
markedly O
elevated B-Lab_value
PTH B-Diagnostic_procedure
, O
and O
was O
younger B-Age
than I-Age
50 I-Age
years I-Age
old I-Age
, O
so O
it O
was O
decided O
that O
surgery B-Therapeutic_procedure
was O
the O
best O
choice O
in O
management O
. O
The O
patient O
was O
brought B-Clinical_event
to O
the O
operating B-Nonbiological_location
room I-Nonbiological_location
and O
underwent O
a O
parathyroidectomy B-Therapeutic_procedure
. O
The O
surgeon O
found O
the O
parathyroid B-Biological_structure
gland I-Biological_structure
to O
be O
firm B-Sign_symptom
and O
densely B-Detailed_description
adherent B-Sign_symptom
to O
the O
thyroid B-Biological_structure
capsule I-Biological_structure
and O
overlying O
strap B-Biological_structure
muscle I-Biological_structure
, O
making O
it O
difficult O
to O
dissect B-Therapeutic_procedure
. O
There O
was O
no O
visible O
invasion B-Sign_symptom
into O
the O
capsule B-Biological_structure
, O
surrounding O
muscle B-Biological_structure
or O
regional O
lymph B-Biological_structure
nodes I-Biological_structure
. O
The O
resected B-Diagnostic_procedure
specimen I-Diagnostic_procedure
was O
noted O
to O
be O
brownish O
grey O
in O
colour O
with O
scattered B-Detailed_description
necrotic B-Sign_symptom
foci I-Sign_symptom
, O
and O
irregular O
texture O
. O
On O
postoperative O
pathology B-Diagnostic_procedure
, O
the O
specimen O
was O
confirmed O
positive O
for O
parathyroid B-Disease_disorder
carcinoma I-Disease_disorder
with O
capsular B-Biological_structure
invasion B-Sign_symptom
, O
focal B-Detailed_description
tumour B-Sign_symptom
necrosis I-Sign_symptom
, O
reactive B-Detailed_description
fibrosis B-Sign_symptom
and O
local O
skeletal B-Biological_structure
muscle I-Biological_structure
invasion B-Sign_symptom
( O
figures O
1 O
and O
2 O
) O
. O
Margins B-Therapeutic_procedure
were I-Therapeutic_procedure
resected I-Therapeutic_procedure
. O
Immunohistochemical B-Diagnostic_procedure
stains I-Diagnostic_procedure
showed O
increased B-Lab_value
Ki-67 B-Diagnostic_procedure
reactivity O
as O
well O
as O
strong B-Lab_value
Bcl-1 B-Diagnostic_procedure
( O
cyclin B-Diagnostic_procedure
D1 I-Diagnostic_procedure
) O
reactivity O
, O
which O
support O
the O
diagnosis O
of O
parathyroid B-Disease_disorder
carcinoma I-Disease_disorder
( O
figure O
3 O
) O
. O
Additionally O
, O
P57 B-Diagnostic_procedure
staining I-Diagnostic_procedure
was O
negative B-Lab_value
. O
Although O
most O
reports O
of O
parathyroid B-Disease_disorder
carcinomas I-Disease_disorder
are O
associated O
with O
marked O
hypercalcaemia B-Sign_symptom
, O
non-functioning O
cancers O
in O
patients O
tend O
to O
behave O
more O
aggressively O
.1 O
Owing O
to O
the O
severity O
and O
uncertainty O
of O
the O
lesion O
, O
the O
patient O
was O
followed B-Clinical_event
up I-Clinical_event
postoperatively O
for O
repeat O
imaging B-Diagnostic_procedure
to O
determine O
if O
residual B-Detailed_description
tumour B-Sign_symptom
remained O
. O
Repeat O
sestamibi B-Diagnostic_procedure
and O
positron B-Diagnostic_procedure
emission I-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
PET B-Diagnostic_procedure
) O
scan O
revealed O
residual O
activity O
along O
the O
surgical O
area O
so O
the O
patient O
subsequently O
underwent O
a O
second O
operation B-Therapeutic_procedure
for O
a O
radical B-Detailed_description
left B-Detailed_description
neck B-Biological_structure
dissection B-Therapeutic_procedure
and O
left B-Detailed_description
hemithyroidectomy B-Therapeutic_procedure
. O
The O
patient O
recovered B-Sign_symptom
very O
well O
postoperatively O
and O
it O
has O
now O
been O
3 B-Date
years I-Date
since O
the O
second O
surgery B-Therapeutic_procedure
. O
The O
patient O
continues O
to O
do O
very O
well O
and O
is O
followed B-Clinical_event
up I-Clinical_event
every O
3 O
months O
to O
monitor O
serum B-Detailed_description
PTH B-Diagnostic_procedure
and O
calcium B-Diagnostic_procedure
levels O
. O
She O
no O
longer O
reports O
of O
neck B-Biological_structure
and O
shoulder B-Biological_structure
pain B-Sign_symptom
. O
Sometimes O
the O
patient O
's O
blood B-Diagnostic_procedure
tests I-Diagnostic_procedure
show O
marginally B-Lab_value
elevated I-Lab_value
PTH B-Diagnostic_procedure
levels O
, O
however O
, O
she O
remains O
eucalcaemic B-Sign_symptom
and O
follow-up O
nuclear B-Diagnostic_procedure
scans I-Diagnostic_procedure
and O
PET B-Diagnostic_procedure
scans O
continue O
to O
be O
negative B-Lab_value
. O
The O
patient O
will O
continue O
to O
be O
monitored B-Clinical_event
every O
3 O
months O
indefinitely O
. O
Our O
patient O
( O
ID O
73387 O
) O
is O
a O
female B-Sex
child B-Age
, O
born B-Clinical_event
by O
an O
emergency B-Detailed_description
caesarean B-Therapeutic_procedure
section I-Therapeutic_procedure
at O
34 O
weeks O
of O
gestation O
to O
consanguineous O
, O
first-cousin O
British O
Pakistani O
parents O
. O
Antenatal B-Diagnostic_procedure
scans I-Diagnostic_procedure
showed O
that O
she O
was O
small B-Lab_value
for O
her O
gestation O
, O
weighing B-Diagnostic_procedure
1.19 B-Lab_value
kg I-Lab_value
at O
birth B-Clinical_event
with O
a O
head B-Diagnostic_procedure
circumference I-Diagnostic_procedure
of O
26.7 B-Lab_value
cm I-Lab_value
, O
considerably B-Lab_value
below I-Lab_value
the I-Lab_value
0.4 I-Lab_value
th I-Lab_value
centile I-Lab_value
. O
Induction B-Therapeutic_procedure
of I-Therapeutic_procedure
labour I-Therapeutic_procedure
had O
been O
attempted O
because O
of O
the O
growth B-Sign_symptom
retardation I-Sign_symptom
but O
had O
failed O
, O
leading O
to O
the O
emergency B-Detailed_description
caesarean B-Therapeutic_procedure
section I-Therapeutic_procedure
. O
The O
Apgar B-Diagnostic_procedure
scores I-Diagnostic_procedure
were O
4 B-Lab_value
at O
1 B-Detailed_description
min I-Detailed_description
, O
7 B-Lab_value
at O
5 B-Detailed_description
min I-Detailed_description
and O
9 B-Lab_value
at O
10 B-Detailed_description
min I-Detailed_description
. O
She O
was O
admitted B-Clinical_event
to O
the O
neonatal B-Nonbiological_location
intensive I-Nonbiological_location
care I-Nonbiological_location
unit I-Nonbiological_location
for O
continuous B-Therapeutic_procedure
positive I-Therapeutic_procedure
airway I-Therapeutic_procedure
pressure I-Therapeutic_procedure
ventilation I-Therapeutic_procedure
. O
At O
a O
few O
hours O
of O
age O
, O
she O
developed O
a O
severe B-Severity
lactic B-Sign_symptom
acidosis I-Sign_symptom
. O
The O
initial O
lactic B-Diagnostic_procedure
acid I-Diagnostic_procedure
concentration I-Diagnostic_procedure
was O
22 B-Lab_value
mmol/l I-Lab_value
and O
subsequently B-Detailed_description
increased B-Lab_value
to O
63 B-Lab_value
mmol/l I-Lab_value
( O
normal O
range O
, O
0.7 O
– O
2.1 O
mmol/l O
) O
. O
She O
was O
treated O
with O
intravenous O
infusions O
of O
sodium O
bicarbonate O
and O
Tris-hydroxymethyl O
aminomethane O
( O
THAM O
) O
, O
but O
it O
was O
never O
possible O
to O
correct O
the O
metabolic B-Sign_symptom
acidosis I-Sign_symptom
. O
She O
also O
developed O
hypoglycaemia B-Sign_symptom
within O
hours O
of O
birth B-Clinical_event
that O
was O
corrected O
with O
an O
intravenous O
infusion O
of O
15 O
% O
glucose O
( O
7.8 O
mg/kg/min O
) O
. O
The O
ammonia B-Diagnostic_procedure
concentration I-Diagnostic_procedure
was O
normal B-Lab_value
. O
Urine B-Detailed_description
organic B-Diagnostic_procedure
acid I-Diagnostic_procedure
profile I-Diagnostic_procedure
showed O
massive B-Severity
excretion B-Lab_value
of O
lactic B-Diagnostic_procedure
acid I-Diagnostic_procedure
and O
increased B-Lab_value
phenolic B-Diagnostic_procedure
acids I-Diagnostic_procedure
, O
especially B-Lab_value
hydroxyphenyllactate I-Lab_value
. O
Plasma B-Detailed_description
amino B-Diagnostic_procedure
acids I-Diagnostic_procedure
showed O
raised B-Lab_value
concentrations O
of O
alanine B-Diagnostic_procedure
and O
glutamine B-Diagnostic_procedure
( O
1567 B-Lab_value
and O
1369 B-Lab_value
μmol/l I-Lab_value
, O
respectively O
) O
, O
consistent O
with O
the O
lactic B-Sign_symptom
acidosis I-Sign_symptom
; O
several O
other B-Diagnostic_procedure
amino I-Diagnostic_procedure
acids I-Diagnostic_procedure
were O
also O
mildly O
increased B-Lab_value
. O
There O
was O
gross B-Severity
generalised B-Detailed_description
aminoaciduria B-Sign_symptom
. O
Blood B-Detailed_description
acylcarnitine B-Diagnostic_procedure
analysis I-Diagnostic_procedure
was O
normal B-Lab_value
. O
Echocardiography B-Diagnostic_procedure
showed O
a O
structurally B-Lab_value
normal I-Lab_value
heart B-Biological_structure
and O
good B-Lab_value
ventricular B-Diagnostic_procedure
function I-Diagnostic_procedure
. O
Cranial B-Biological_structure
ultrasound B-Diagnostic_procedure
showed O
bilateral B-Detailed_description
intraventricular B-Biological_structure
cysts B-Sign_symptom
within O
the O
frontal B-Biological_structure
horns I-Biological_structure
and I-Biological_structure
anterior I-Biological_structure
portions I-Biological_structure
of I-Biological_structure
the I-Biological_structure
lateral I-Biological_structure
ventricles I-Biological_structure
. O
The O
left-sided B-Detailed_description
cysts B-Sign_symptom
were O
larger O
, O
up O
to O
15 O
mm O
in O
diameter O
, O
whereas O
the O
largest O
cyst B-Sign_symptom
on O
the O
right O
was O
8 O
mm O
in O
diameter O
. O
The O
choroid B-Biological_structure
plexuses I-Biological_structure
were O
hyperechoic B-Sign_symptom
and O
irregular B-Sign_symptom
, O
suggesting O
previous O
intraventricular B-Disease_disorder
haemorrhage I-Disease_disorder
. O
Abdominal B-Biological_structure
ultrasound B-Diagnostic_procedure
showed O
a O
distended B-Sign_symptom
urinary B-Biological_structure
bladder I-Biological_structure
but O
was O
otherwise O
unremarkable O
. O
There O
was O
severe B-Severity
coagulopathy B-Disease_disorder
with O
an O
extended B-Lab_value
prothrombin B-Diagnostic_procedure
time I-Diagnostic_procedure
of O
47.7 B-Lab_value
s I-Lab_value
( O
normal O
12.3 O
– O
16.6 O
s O
) O
, O
a O
very B-Lab_value
low I-Lab_value
plasma B-Diagnostic_procedure
albumin I-Diagnostic_procedure
of O
7 B-Lab_value
g/l I-Lab_value
( O
normal O
35 O
– O
50 O
g/l O
) O
, O
otherwise O
normal B-Lab_value
liver B-Diagnostic_procedure
function I-Diagnostic_procedure
tests I-Diagnostic_procedure
but O
a O
raised B-Lab_value
creatine B-Diagnostic_procedure
kinase I-Diagnostic_procedure
of O
2700 B-Lab_value
U/l I-Lab_value
( O
normal O
< O
300 O
U/l O
) O
. O
She O
was O
transferred B-Clinical_event
to O
a O
tertiary B-Nonbiological_location
centre I-Nonbiological_location
because O
of O
her O
worsening O
metabolic B-Sign_symptom
acidosis I-Sign_symptom
. O
She O
started O
having O
seizures B-Sign_symptom
at O
∼ B-Date
48 I-Date
h I-Date
of I-Date
age I-Date
. O
Despite O
infusions O
of O
bicarbonate O
and O
THAM O
, O
her O
acidosis B-Sign_symptom
continued O
to O
worsen O
. O
Muscle B-Biological_structure
and O
skin B-Biological_structure
biopsies B-Diagnostic_procedure
were O
performed O
and O
the O
family O
agreed O
to O
the O
withdrawal O
of O
intensive B-Therapeutic_procedure
care I-Therapeutic_procedure
treatment I-Therapeutic_procedure
. O
She O
died B-Clinical_event
aged O
55 B-Date
h. I-Date
All O
documented O
studies O
were O
approved O
and O
performed O
under O
the O
ethical O
guidelines O
issued O
by O
each O
of O
our O
Institutions O
for O
clinical O
studies O
, O
with O
written O
informed O
consent O
obtained O
from O
the O
family O
. O
A O
77-year-old B-Age
woman B-Sex
with O
dysphagia B-Sign_symptom
presented B-Clinical_event
with O
a O
two-week O
history O
of O
rash B-Sign_symptom
characterized O
by O
brown O
plaques B-Sign_symptom
with O
erythematous B-Detailed_description
borders I-Detailed_description
and O
overlying B-Detailed_description
thick I-Detailed_description
scales I-Detailed_description
involving O
the O
face B-Biological_structure
and O
a O
prior O
percutaneous B-Diagnostic_procedure
endoscopic I-Diagnostic_procedure
gastrostomy I-Diagnostic_procedure
( O
PEG B-Diagnostic_procedure
) O
tube O
site B-Biological_structure
( O
Fig. O
1a O
, O
c O
) O
. O
No O
oral B-Biological_structure
or O
conjunctival B-Biological_structure
involvement B-Sign_symptom
was O
present O
. O
She O
had O
been O
receiving O
parenteral O
nutrition O
for O
two O
months O
following O
removal O
of O
the O
PEG B-Diagnostic_procedure
tube I-Diagnostic_procedure
due O
to O
infection B-Disease_disorder
. O
Although O
the O
differential O
diagnosis O
included O
drug B-Disease_disorder
hypersensitivity I-Disease_disorder
, O
autoimmune B-Disease_disorder
disorders I-Disease_disorder
and O
nutritional B-Disease_disorder
deficiency I-Disease_disorder
, O
the O
rash B-Sign_symptom
appearance O
was O
most O
consistent O
with O
acrodermatitis B-Disease_disorder
enteropathica-like I-Disease_disorder
eruption B-Sign_symptom
secondary O
to O
zinc B-Disease_disorder
deficiency I-Disease_disorder
. O
Her O
serum B-Detailed_description
zinc B-Diagnostic_procedure
level O
was O
12 B-Lab_value
mcg/dL I-Lab_value
( O
normal O
, O
55 O
– O
150 O
mcg/dL O
) O
, O
and O
the O
rash B-Sign_symptom
resolved O
within B-Date
one I-Date
week I-Date
of O
parenteral O
zinc O
supplementation O
( O
Fig. O
1b O
, O
d O
) O
. O
Zinc O
is O
essential O
for O
protein O
synthesis O
and O
wound O
healing O
. O
Acrodermatitis O
enteropathica O
presents O
in O
infancy O
as O
a O
periorificial O
desquamative O
dermatitis O
, O
resulting O
from O
an O
autosomal O
recessive O
mutation O
that O
impairs O
zinc O
absorption O
. O
A O
similar O
syndrome O
may O
occur O
due O
to O
nutritional O
zinc O
deficiency O
, O
and O
has O
been O
reported O
in O
the O
setting O
of O
parenteral O
nutrition O
that O
fails O
to O
include O
zinc O
supplementation O
; O
a O
prompt O
response O
to O
supplementation O
helps O
to O
confirm O
the O
diagnosis O
. O
A O
recent O
national O
shortage O
of O
parenteral O
zinc O
in O
the O
United B-Nonbiological_location
States I-Nonbiological_location
likely O
contributed O
to O
this O
patient O
’s O
presentation O
. O
A O
38-year-old B-Age
woman B-Sex
presented B-Clinical_event
to O
our O
Emergency B-Nonbiological_location
Department I-Nonbiological_location
with O
severe B-Severity
abdominal B-Biological_structure
pain B-Sign_symptom
. O
She O
had O
no O
history O
of O
drug O
use O
or O
constipation O
. O
She O
said O
that O
she O
had O
intermittent B-Detailed_description
bloody B-Detailed_description
diarrhea B-Sign_symptom
. O
Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
rebound B-Detailed_description
tenderness B-Sign_symptom
and O
guarding B-Sign_symptom
over O
the O
abdomen B-Biological_structure
. O
Stool B-Diagnostic_procedure
microscopy I-Diagnostic_procedure
was O
negative B-Lab_value
for O
amoeba B-Diagnostic_procedure
trophozoites I-Diagnostic_procedure
or O
any O
parasites B-Diagnostic_procedure
. O
Fecal B-Diagnostic_procedure
occult I-Diagnostic_procedure
blood I-Diagnostic_procedure
was O
found B-Lab_value
. O
Sedimentation B-Diagnostic_procedure
was O
27 B-Lab_value
mm/s I-Lab_value
, O
CRP B-Diagnostic_procedure
( O
nephelometry B-Diagnostic_procedure
) O
was O
65.6 B-Lab_value
mg/L I-Lab_value
( O
normal O
range O
0 O
– O
5 O
) O
, O
anti-nuclear B-Diagnostic_procedure
antibody I-Diagnostic_procedure
was O
0.4 B-Lab_value
( O
0 O
– O
0.8 O
negative O
) O
, O
anti-ds B-Diagnostic_procedure
DNA I-Diagnostic_procedure
< B-Lab_value
10 I-Lab_value
( O
< O
20 O
negative O
) O
, O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
was O
14.98 B-Lab_value
( O
normal O
range O
4 O
– O
10 O
) O
, O
hemoglobin B-Diagnostic_procedure
level O
was O
10.9 B-Lab_value
, O
neutro-phil B-Diagnostic_procedure
count I-Diagnostic_procedure
was O
13.14 B-Lab_value
, O
platelet B-Diagnostic_procedure
count I-Diagnostic_procedure
was O
473 B-Lab_value
( O
100 O
– O
300 O
) O
, O
urea B-Diagnostic_procedure
level O
was O
17 B-Lab_value
mg/dl I-Lab_value
, O
BUN B-Diagnostic_procedure
level O
was O
7.94 B-Lab_value
mg/dl I-Lab_value
, O
creatinine B-Diagnostic_procedure
level O
was O
0.56 B-Lab_value
mg/dl I-Lab_value
, O
AST B-Diagnostic_procedure
was O
20 B-Lab_value
U/L I-Lab_value
, O
and O
ALT B-Diagnostic_procedure
was O
24 B-Lab_value
U/L I-Lab_value
. O
HIV B-Diagnostic_procedure
was O
negative B-Lab_value
. O
Abdominal B-Biological_structure
ultrasound B-Diagnostic_procedure
scanning O
showed O
free B-Sign_symptom
fluid I-Sign_symptom
at O
the O
right B-Biological_structure
paracolic I-Biological_structure
, O
perihepatic B-Biological_structure
, O
left B-Biological_structure
paracolic I-Biological_structure
gutters B-Biological_structure
and O
pelvis B-Biological_structure
. O
Upon O
detection O
of O
air-fluid B-Sign_symptom
level I-Sign_symptom
and O
free B-Sign_symptom
air I-Sign_symptom
under B-Biological_structure
the I-Biological_structure
diaphragm I-Biological_structure
on O
erect B-Detailed_description
abdominal B-Biological_structure
x-ray B-Diagnostic_procedure
, O
emergency B-Detailed_description
laparotomy B-Therapeutic_procedure
was O
performed O
. O
In O
the O
operation O
, O
multiple B-Detailed_description
perforation B-Sign_symptom
areas O
were O
found O
in O
the O
sigmoid B-Biological_structure
colon I-Biological_structure
, O
descending B-Biological_structure
colon I-Biological_structure
, O
and O
transverse B-Biological_structure
colon I-Biological_structure
. O
Wide B-Detailed_description
resection B-Therapeutic_procedure
of O
the O
transverse B-Biological_structure
colon I-Biological_structure
with O
descending B-Biological_structure
and I-Biological_structure
sigmoid I-Biological_structure
colon I-Biological_structure
resection B-Therapeutic_procedure
was O
undertaken O
( O
Figure O
1 O
) O
. O
Pathergy B-Diagnostic_procedure
test I-Diagnostic_procedure
was O
positive B-Lab_value
. O
The O
patient O
had O
recurrent O
oral B-Biological_structure
and O
genital B-Biological_structure
aphthous B-Detailed_description
ulcers B-Disease_disorder
4 B-Lab_value
– I-Lab_value
5 I-Lab_value
times I-Lab_value
within B-Date
the I-Date
past I-Date
year I-Date
. O
Eye B-Diagnostic_procedure
examination I-Diagnostic_procedure
results O
were O
normal B-Lab_value
. O
Computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
revealed O
extensive B-Detailed_description
thrombus B-Disease_disorder
within O
the O
inferior B-Biological_structure
vena I-Biological_structure
cava I-Biological_structure
extending O
through O
the O
right B-Biological_structure
and I-Biological_structure
middle I-Biological_structure
hepatic I-Biological_structure
vein I-Biological_structure
( O
Figure O
2 O
) O
. O
The O
patient O
received O
corticosteroid O
, O
anticoagulant O
, O
and O
immunosuppressive B-Therapeutic_procedure
therapy I-Therapeutic_procedure
. O
Our O
patient O
is O
still O
alive B-Sign_symptom
and O
healthy B-Sign_symptom
53 B-Date
weeks I-Date
later I-Date
( O
Figure O
3 O
) O
. O
In O
macroscopy B-Diagnostic_procedure
, O
the O
transverse B-Diagnostic_procedure
colon I-Diagnostic_procedure
was O
50 O
cm O
and O
sigmoid B-Lab_value
and O
descending B-Diagnostic_procedure
colon I-Diagnostic_procedure
specimens I-Diagnostic_procedure
were O
27 O
cm O
in O
length O
. O
Specimens B-Diagnostic_procedure
of I-Diagnostic_procedure
both I-Diagnostic_procedure
colon I-Diagnostic_procedure
segments I-Diagnostic_procedure
were O
4 O
cm O
in O
diameter O
. O
Perforation B-Disease_disorder
areas O
were O
evident O
in O
the O
serosal B-Biological_structure
surface I-Biological_structure
. O
Colonic B-Biological_structure
wall I-Biological_structure
and O
bowel B-Biological_structure
mucosa I-Biological_structure
was O
edematous B-Sign_symptom
and O
hyperemic B-Sign_symptom
. O
Plicae B-Diagnostic_procedure
were O
regular B-Lab_value
in O
their O
course O
. O
There O
were O
3 B-Lab_value
roundish O
, O
punched-out B-Detailed_description
perforations B-Disease_disorder
in O
the O
transverse B-Biological_structure
colon I-Biological_structure
and O
4 B-Lab_value
in O
the O
descending B-Biological_structure
and I-Biological_structure
sigmoid I-Biological_structure
colon I-Biological_structure
, O
which O
were O
somewhat O
separate B-Detailed_description
from I-Detailed_description
the I-Detailed_description
colonic I-Detailed_description
wall I-Detailed_description
, O
with O
the O
largest O
being O
2 O
cm O
in O
diameter O
( O
Figure O
4 O
) O
. O
There O
were O
multiple B-Detailed_description
ulcers B-Disease_disorder
( O
the O
largest O
was O
1 O
cm O
in O
diameter O
) O
in O
different O
locations O
, O
which O
were O
not B-Detailed_description
merging I-Detailed_description
together I-Detailed_description
, O
and O
were O
somewhat B-Detailed_description
separate I-Detailed_description
from I-Detailed_description
the I-Detailed_description
surrounding I-Detailed_description
mucosa I-Detailed_description
via I-Detailed_description
a I-Detailed_description
certain I-Detailed_description
limit I-Detailed_description
, O
covered B-Detailed_description
with I-Detailed_description
exudate I-Detailed_description
and O
surrounded B-Detailed_description
by O
a O
hyperemic B-Sign_symptom
region I-Sign_symptom
. O
There O
were O
no O
macroscopic B-Sign_symptom
lymph I-Sign_symptom
nodes I-Sign_symptom
in O
the O
serosa B-Biological_structure
. O
Numerous O
samples O
were O
taken O
from O
ulcerated O
and O
perforated O
regions O
and O
normal O
mucosa O
. O
The O
samples O
were O
submitted O
for O
routine O
microscopic B-Diagnostic_procedure
tissue I-Diagnostic_procedure
follow-up I-Diagnostic_procedure
. O
Hematoxylin-eosin B-Diagnostic_procedure
, O
tissue B-Diagnostic_procedure
Giemsa I-Diagnostic_procedure
and O
PAS-stained B-Diagnostic_procedure
slides I-Diagnostic_procedure
were O
prepared O
for O
examination O
. O
In O
microscopic O
examination O
, O
there O
were O
neutrophil B-Biological_structure
leukocyte I-Biological_structure
and O
lymphocyte B-Biological_structure
reaction B-Sign_symptom
around O
and O
within O
the O
walls B-Biological_structure
and I-Biological_structure
lumens I-Biological_structure
of I-Biological_structure
arterioles I-Biological_structure
, O
and O
venules B-Sign_symptom
around O
the O
perforated B-Detailed_description
and O
ulcerated B-Detailed_description
lesions B-Sign_symptom
( O
Figures O
5 O
and O
and6 O
) O
.6 O
) O
. O
There O
were O
well-organized B-Detailed_description
thrombi B-Sign_symptom
and O
intimal B-Sign_symptom
proliferation I-Sign_symptom
within O
some B-Biological_structure
vessels I-Biological_structure
( O
Figures O
7 O
and O
and8 O
) O
.8 O
) O
. O
There O
was O
marked O
acute B-Detailed_description
peritonitis B-Disease_disorder
. O
Surface B-Diagnostic_procedure
epithelium I-Diagnostic_procedure
and O
colonic B-Diagnostic_procedure
crypts I-Diagnostic_procedure
were O
regular B-Lab_value
within O
the O
colonic B-Biological_structure
mucosa I-Biological_structure
apart O
from O
the O
ulcerated O
or O
perforated O
lesions O
. O
Samples O
were O
free O
of O
parasites B-Disease_disorder
or O
their O
eggs O
. O
A O
35-year-old B-Age
woman B-Sex
was O
admitted B-Clinical_event
with O
a O
5-day O
history O
of O
increasing O
drowsiness B-Sign_symptom
, O
fatigue B-Sign_symptom
, O
personality B-Sign_symptom
changes I-Sign_symptom
, O
generalised B-Detailed_description
weakness B-Sign_symptom
and O
deteriorating O
mobility B-Diagnostic_procedure
. O
Her O
medical O
history O
included O
a O
10-year O
history O
of O
schizo-affective O
disorder O
, O
lithium-induced O
diabetes O
insipidus O
and O
hypothyroidism O
. O
Her O
medications O
included O
sodium O
valproate O
1 O
g O
twice O
daily O
, O
carbamazepine O
, O
quetiapine O
and O
lithium O
. O
On O
admission O
, O
the O
patient O
was O
drowsy B-Sign_symptom
, O
difficult B-Sign_symptom
to I-Sign_symptom
rouse I-Sign_symptom
( O
sleeping O
all B-Detailed_description
night I-Detailed_description
and I-Detailed_description
in I-Detailed_description
the I-Detailed_description
afternoon I-Detailed_description
) O
. O
Her O
Glasgow B-Diagnostic_procedure
Coma I-Diagnostic_procedure
Scale I-Diagnostic_procedure
( O
GCS B-Diagnostic_procedure
) O
was O
14/15 O
, O
her O
abbreviated O
mini-mental B-Diagnostic_procedure
test I-Diagnostic_procedure
score I-Diagnostic_procedure
was O
6/10 O
and O
she O
was O
noted O
to O
be O
slow O
in O
her O
responses O
. O
Neurological B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
reduced O
power B-Diagnostic_procedure
in O
her O
lower B-Biological_structure
limbs I-Biological_structure
( O
3 O
– O
4/5 O
) O
in O
a O
pyramidal O
distribution O
, O
and O
brisk O
reflexes B-Diagnostic_procedure
with O
intact O
sensation B-Diagnostic_procedure
in O
all B-Detailed_description
modalities I-Detailed_description
. O
Cardiovascular B-Biological_structure
, O
respiratory B-Biological_structure
and O
gastrointestinal B-Biological_structure
examinations B-Diagnostic_procedure
were O
unremarkable B-Lab_value
and O
there O
were O
no O
demonstrable O
features O
of O
hepatic B-Disease_disorder
disease I-Disease_disorder
. O
Routine B-Detailed_description
biochemistry B-Diagnostic_procedure
was O
unremarkable O
. O
The O
patient O
's O
alanine B-Diagnostic_procedure
transaminase I-Diagnostic_procedure
was O
7 B-Lab_value
u/L I-Lab_value
( O
1 O
– O
15 O
) O
, O
alkaline B-Diagnostic_procedure
phosphatase I-Diagnostic_procedure
61 B-Lab_value
u/L I-Lab_value
( O
30 O
– O
130 O
) O
, O
γ-glutamyl B-Diagnostic_procedure
transferase I-Diagnostic_procedure
17 B-Lab_value
u/L I-Lab_value
( O
< O
45 O
) O
and O
bilirubin B-Diagnostic_procedure
was O
6 B-Lab_value
μmol/L I-Lab_value
( O
< O
21 O
) O
. O
She O
had O
normal O
serum B-Detailed_description
B12 B-Diagnostic_procedure
and O
folate B-Diagnostic_procedure
levels O
, O
and O
normal O
thyroid B-Diagnostic_procedure
function I-Diagnostic_procedure
tests I-Diagnostic_procedure
. O
Serum B-Detailed_description
lithium B-Diagnostic_procedure
levels O
were O
within O
the O
therapeutic O
range O
. O
Her O
serum B-Detailed_description
ammonia B-Diagnostic_procedure
was O
47 B-Lab_value
μmol/L I-Lab_value
( O
11.2 O
– O
35.4 O
) O
and O
valproate B-Diagnostic_procedure
concentrations O
were O
elevated O
140 B-Lab_value
mg/L I-Lab_value
( O
50 O
– O
100 O
) O
. O
Brain B-Biological_structure
imaging B-Diagnostic_procedure
including O
CT B-Diagnostic_procedure
and O
MRI B-Diagnostic_procedure
did O
not O
show O
any O
haemorrhage B-Sign_symptom
or O
intracranial B-Biological_structure
mass B-Sign_symptom
. O
Lumbar B-Diagnostic_procedure
puncture I-Diagnostic_procedure
demonstrated O
clear O
cerebrospinal B-Biological_structure
fluid I-Biological_structure
( O
white B-Diagnostic_procedure
cell I-Diagnostic_procedure
count I-Diagnostic_procedure
< O
1 O
× O
106/L O
, O
protein B-Diagnostic_procedure
0.25 B-Lab_value
g/L I-Lab_value
( O
0.2 O
– O
0.4 O
) O
) O
. O
EEG B-Diagnostic_procedure
demonstrated O
mild B-Severity
variable O
slowing B-Sign_symptom
and O
irregularity B-Sign_symptom
of I-Sign_symptom
background I-Sign_symptom
activity I-Sign_symptom
( O
likely O
due O
to O
medication O
) O
. O
The O
differential O
diagnosis O
included O
encephalitis B-Disease_disorder
, O
Guillain-Barré B-Disease_disorder
syndrome I-Disease_disorder
and O
acute B-Disease_disorder
disseminated I-Disease_disorder
encephalomyelitis I-Disease_disorder
( O
ADEM B-Disease_disorder
) O
, O
which O
were O
excluded O
through O
our O
investigations O
. O
In O
view O
of O
the O
raised B-Lab_value
valproate B-Diagnostic_procedure
and O
ammonia B-Diagnostic_procedure
levels O
, O
a O
diagnosis O
of O
valproate B-Disease_disorder
hyperammonaemic I-Disease_disorder
encephalopathy I-Disease_disorder
( O
VHE B-Disease_disorder
) O
was O
made O
at O
this O
point O
The O
dose O
of O
sodium O
valproate O
was O
reduced O
by O
half O
rather O
than O
being O
completely O
withdrawn O
. O
This O
was O
due O
to O
the O
complex O
and O
challenging O
nature O
of O
managing O
the O
patient O
's O
schizo-affective B-Disease_disorder
disorder I-Disease_disorder
. O
Within B-Date
3 I-Date
days I-Date
, O
there O
was O
evident O
clinical O
improvement B-Lab_value
in O
her O
mental B-Diagnostic_procedure
status I-Diagnostic_procedure
. O
The O
patient O
was O
able O
to O
sit O
and O
communicate O
with O
the O
team O
, O
and O
her O
abbreviated B-Diagnostic_procedure
mental I-Diagnostic_procedure
test I-Diagnostic_procedure
score I-Diagnostic_procedure
improved B-Lab_value
to O
10/10 B-Lab_value
. O
The O
serum B-Detailed_description
ammonia B-Diagnostic_procedure
normalised B-Lab_value
and O
valproate B-Diagnostic_procedure
levels O
decreased B-Lab_value
to O
the O
therapeutic B-Lab_value
range I-Lab_value
. O
After B-Date
4 I-Date
days I-Date
she O
was O
discharged B-Clinical_event
home B-Nonbiological_location
. O
Results O
of O
investigations B-Diagnostic_procedure
of O
her O
urea B-Detailed_description
cycle I-Detailed_description
were O
awaited O
. O
Three B-Date
weeks I-Date
postdischarge B-Clinical_event
, O
the O
patient O
was O
clinically O
stable B-Lab_value
in O
terms O
of O
mental B-Diagnostic_procedure
functioning I-Diagnostic_procedure
, O
having O
had O
no O
further O
episodes O
of O
confusion B-Sign_symptom
or O
drowsiness B-Sign_symptom
. O
However O
, O
she O
continued O
to O
have O
fatigue B-Sign_symptom
and O
walking B-Sign_symptom
difficulties I-Sign_symptom
( O
due O
to O
residual B-Detailed_description
leg B-Biological_structure
weakness B-Sign_symptom
) O
. O
Results O
of O
her O
serum B-Detailed_description
amino B-Diagnostic_procedure
acids I-Diagnostic_procedure
revealed O
that O
our O
patient O
had O
carnitine B-Disease_disorder
deficiency I-Disease_disorder
evident O
by O
low B-Lab_value
acyl-carnitine B-Diagnostic_procedure
, O
low B-Lab_value
free B-Detailed_description
serum B-Detailed_description
carnitine B-Diagnostic_procedure
( O
14.2 B-Lab_value
μmol/L I-Lab_value
, O
normal O
range O
: O
23 O
– O
52 O
) O
and O
low B-Lab_value
total B-Detailed_description
serum B-Detailed_description
carnitine B-Diagnostic_procedure
( O
19.9 B-Lab_value
μmol/L I-Lab_value
, O
normal O
range O
: O
27 O
– O
63 O
) O
. O
She O
was O
started O
on O
oral O
carnitine O
1 O
g O
twice O
daily O
. O
Within B-Date
2 I-Date
weeks I-Date
, O
her O
symptoms B-Sign_symptom
resolved O
completely O
with O
normalisation B-Lab_value
of O
serum B-Detailed_description
carnitine B-Diagnostic_procedure
levels O
( O
free B-Detailed_description
carnitine B-Diagnostic_procedure
25.2 B-Lab_value
μmol/L I-Lab_value
and O
total B-Detailed_description
carnitine B-Diagnostic_procedure
of O
41.3 B-Lab_value
μmol/L I-Lab_value
) O
. O
The O
sodium O
valproate O
was O
initially O
stopped O
completely O
, O
but O
due O
to O
a O
serious O
relapse B-Detailed_description
of O
the O
patient O
's O
schizo-affective B-Disease_disorder
disorder I-Disease_disorder
, O
it O
was O
restarted O
and O
she O
is O
now O
well B-Sign_symptom
on O
valproate O
1 O
g O
once O
daily O
and O
long-term B-Detailed_description
carnitine O
supplements O
. O
A O
33-year-old B-Age
man B-Sex
presented B-Clinical_event
with O
left B-Biological_structure
flank I-Biological_structure
dull B-Detailed_description
ache B-Sign_symptom
. O
On O
the O
abdominal B-Biological_structure
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
, O
a O
solid B-Detailed_description
renal B-Biological_structure
mass B-Sign_symptom
in O
the O
upper B-Biological_structure
portion I-Biological_structure
of I-Biological_structure
the I-Biological_structure
left I-Biological_structure
kidney I-Biological_structure
was O
identified O
. O
The O
mass O
was O
measured O
2.8 O
cm O
× O
2.8 O
cm O
× O
2.5 O
cm O
in O
size O
, O
was O
well-defined B-Detailed_description
. O
The O
patient O
had O
no O
other B-Sign_symptom
abnormal I-Sign_symptom
findings I-Sign_symptom
, O
such O
as O
suspected O
distant B-Detailed_description
metastasis B-Sign_symptom
or O
lymph B-Biological_structure
node I-Biological_structure
metastasis B-Sign_symptom
. O
Radical B-Detailed_description
nephrectomy B-Therapeutic_procedure
was O
performed O
on O
14/9/2005 B-Date
. O
On O
gross B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
the O
nephrectomy B-Detailed_description
specimen I-Detailed_description
measured O
11.5 O
cm O
× O
6.5 O
cm O
× O
4.5 O
cm O
and O
the O
tumor O
was O
a O
solid B-Detailed_description
, O
grayish-brown O
mass O
measured O
3.5 O
cm O
× O
2.5 O
cm O
× O
2.2 O
cm O
in O
size O
. O
Histologic B-Diagnostic_procedure
examination I-Diagnostic_procedure
demonstrated O
trabecular B-Lab_value
and I-Lab_value
ribbonlike I-Lab_value
patterns I-Lab_value
with O
minimal B-Lab_value
fibrotic I-Lab_value
stroma I-Lab_value
. O
The O
cytoplasm B-Diagnostic_procedure
was O
granular B-Lab_value
and O
eosinophilic B-Lab_value
with O
uniform B-Lab_value
round I-Lab_value
to I-Lab_value
oval I-Lab_value
nuclei I-Lab_value
with O
finely B-Lab_value
stippled I-Lab_value
chromatin I-Lab_value
and O
inconspicuous B-Lab_value
nucleoli I-Lab_value
. O
Mitoses B-Diagnostic_procedure
were O
not B-Lab_value
found I-Lab_value
( O
0 B-Lab_value
per I-Lab_value
10 I-Lab_value
high-power I-Lab_value
fields I-Lab_value
) O
on O
H&E B-Diagnostic_procedure
stain I-Diagnostic_procedure
. O
The O
final O
pathologic B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
well-differentiated B-Detailed_description
neuroendocrine B-Disease_disorder
( I-Disease_disorder
carcinoid I-Disease_disorder
) I-Disease_disorder
tumor I-Disease_disorder
confined O
to O
the O
kidney B-Biological_structure
( O
Fig. O
1 O
) O
. O
Immunohistochemical B-Diagnostic_procedure
stains I-Diagnostic_procedure
demonstrated O
labeling B-Lab_value
with O
chromogranin B-Diagnostic_procedure
, O
neuron-specific B-Diagnostic_procedure
enolase I-Diagnostic_procedure
and O
synaptophysin B-Diagnostic_procedure
( O
Fig. O
2 O
) O
, O
and O
the O
proliferation B-Diagnostic_procedure
index I-Diagnostic_procedure
was O
less B-Lab_value
than I-Lab_value
2 I-Lab_value
% I-Lab_value
as O
measured O
by O
immunohistochemistry B-Diagnostic_procedure
for I-Diagnostic_procedure
Ki-67 I-Diagnostic_procedure
. O
Further O
radiation B-Therapeutic_procedure
and O
chemotherapy O
were O
not O
received O
. O
Nine B-Date
years I-Date
after I-Date
radical O
nephrectomy O
, O
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
of O
the O
abdomen B-Biological_structure
demonstrated O
a O
2 O
cm O
× O
1.8 O
cm O
cyst B-Detailed_description
mass B-Sign_symptom
in O
the O
right B-Biological_structure
liver I-Biological_structure
and O
multiple B-Detailed_description
high B-Sign_symptom
density I-Sign_symptom
shadow I-Sign_symptom
in O
gallbladder B-Biological_structure
. O
No O
enlarged B-Sign_symptom
lymph B-Biological_structure
nodes I-Biological_structure
were O
found O
in O
the O
abdominal B-Biological_structure
cavity I-Biological_structure
. O
Cholecystectomy B-Therapeutic_procedure
and O
extirpation B-Therapeutic_procedure
for O
hepatic B-Disease_disorder
cyst I-Disease_disorder
were O
performed O
by O
laparoscopy B-Therapeutic_procedure
surgery I-Therapeutic_procedure
. O
Histologic B-Diagnostic_procedure
examination I-Diagnostic_procedure
demonstrated O
trabecular B-Lab_value
and I-Lab_value
glandlike I-Lab_value
growth I-Lab_value
( O
Fig. O
3 O
) O
, O
moderate B-Lab_value
and I-Lab_value
uniform I-Lab_value
nuclei I-Lab_value
and O
mitoses B-Diagnostic_procedure
were B-Lab_value
n't I-Lab_value
found I-Lab_value
( O
0 B-Lab_value
per I-Lab_value
10 I-Lab_value
high-power I-Lab_value
fields I-Lab_value
) O
. O
Advanced B-Detailed_description
immunohistochemistry B-Diagnostic_procedure
revealed O
that O
the O
lesion O
was O
positive B-Lab_value
for O
synaptophysin B-Diagnostic_procedure
( O
Fig. O
4 O
) O
and O
CD56 O
, O
but O
negative B-Lab_value
for O
chromogranin B-Diagnostic_procedure
and O
neuron-specific B-Diagnostic_procedure
enolase I-Diagnostic_procedure
. O
These O
features O
are O
supported O
in O
a O
neuroendocrine B-Disease_disorder
tumor I-Disease_disorder
. O
Due O
to O
the O
similar O
pathologic O
characteristics O
between O
the O
primary O
renal O
carcinoid O
tumor O
and O
liver O
tumor O
. O
The O
final O
pathology O
report O
indicated O
a O
carcinoid B-Disease_disorder
tumor I-Disease_disorder
of O
the O
left B-Biological_structure
kidney I-Biological_structure
with O
liver B-Biological_structure
metastasis B-Sign_symptom
. O
A O
36-year-old B-Age
female B-Sex
presented B-Clinical_event
at O
the O
emergency B-Nonbiological_location
department I-Nonbiological_location
with O
aggravating B-Detailed_description
right B-Biological_structure
upper I-Biological_structure
abdominal I-Biological_structure
pain B-Sign_symptom
for O
2 O
hours O
. O
The O
patient O
was O
diagnosed O
hepatitis O
B O
virus O
( O
HBV O
) O
carrier O
for O
several O
years O
and O
non-alcoholics O
. O
No O
other O
specific O
personal O
and O
familial O
medical O
history O
was O
noted O
. O
Initial O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
100/60 B-Lab_value
mmHg I-Lab_value
, O
pulse B-Diagnostic_procedure
rate I-Diagnostic_procedure
70/min B-Lab_value
, O
respiration B-Diagnostic_procedure
rate I-Diagnostic_procedure
20/min B-Lab_value
, O
body B-Diagnostic_procedure
temperature I-Diagnostic_procedure
37.5 B-Lab_value
℃ I-Lab_value
. O
The O
laboratory B-Diagnostic_procedure
findings I-Diagnostic_procedure
were O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
12,000 B-Lab_value
/ I-Lab_value
mm3 I-Lab_value
( O
poly B-Diagnostic_procedure
: O
70 B-Lab_value
% I-Lab_value
) O
, O
hemoglobin B-Diagnostic_procedure
12.8 B-Lab_value
g/dL I-Lab_value
, O
platelet B-Diagnostic_procedure
198,000 B-Lab_value
/ I-Lab_value
mm3 I-Lab_value
, O
prothrombin B-Diagnostic_procedure
time I-Diagnostic_procedure
14.3 B-Lab_value
seconds I-Lab_value
, O
international B-Diagnostic_procedure
normalized I-Diagnostic_procedure
ratio I-Diagnostic_procedure
1.11 B-Lab_value
, O
aspartate B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
22 B-Lab_value
IU/L I-Lab_value
, O
alanine B-Diagnostic_procedure
aminotransferase I-Diagnostic_procedure
12 B-Lab_value
IU/L I-Lab_value
, O
total B-Diagnostic_procedure
bilirubin I-Diagnostic_procedure
0.5 B-Lab_value
mg/dL I-Lab_value
, O
alkaline B-Diagnostic_procedure
phosphatase I-Diagnostic_procedure
134 B-Lab_value
IU/L I-Lab_value
, O
lactate B-Diagnostic_procedure
dehydrogenase I-Diagnostic_procedure
295 B-Lab_value
IU/L I-Lab_value
, O
gamma-glutamyl B-Diagnostic_procedure
transpeptidase I-Diagnostic_procedure
26 B-Lab_value
IU/L I-Lab_value
, O
protein/albumin B-Diagnostic_procedure
6.4 B-Lab_value
/ I-Lab_value
4.0 I-Lab_value
g/dL I-Lab_value
, O
uric B-Diagnostic_procedure
acid I-Diagnostic_procedure
5.0 B-Lab_value
mg/dL I-Lab_value
, O
blood B-Diagnostic_procedure
urea I-Diagnostic_procedure
nitrogen/creatinine I-Diagnostic_procedure
16.6 B-Lab_value
/ I-Lab_value
0.7 I-Lab_value
mg/dL I-Lab_value
. O
And O
serum B-Diagnostic_procedure
viral I-Diagnostic_procedure
markers I-Diagnostic_procedure
were O
HBsAg B-Diagnostic_procedure
( O
+ B-Lab_value
) O
, O
anti-HBs B-Diagnostic_procedure
( O
- B-Lab_value
) O
, O
anti-HBc B-Diagnostic_procedure
( O
+ B-Lab_value
) O
, O
HBeAg B-Diagnostic_procedure
( O
- B-Lab_value
) O
, O
anti-HBe B-Diagnostic_procedure
( O
+ B-Lab_value
) O
, O
HBV-DNA B-Diagnostic_procedure
< B-Lab_value
20 I-Lab_value
IU/mL I-Lab_value
, O
anti-HCV B-Diagnostic_procedure
( O
- B-Lab_value
) O
and O
anti-HIV B-Diagnostic_procedure
( O
- B-Lab_value
) O
. O
The O
patient O
's O
serum B-Diagnostic_procedure
α-fetoprotein I-Diagnostic_procedure
( O
AFP B-Diagnostic_procedure
) O
was O
676.5 B-Lab_value
ng/mL I-Lab_value
and O
carbohydrate B-Diagnostic_procedure
antigen I-Diagnostic_procedure
19-9 I-Diagnostic_procedure
( O
CA19-9 B-Diagnostic_procedure
) O
< B-Lab_value
0.6 I-Lab_value
U/mL I-Lab_value
. O
She O
took O
an O
abdominal B-Biological_structure
CT B-Diagnostic_procedure
scan O
, O
which O
showed O
a O
9 O
cm O
sized O
necrotic B-Detailed_description
mass B-Sign_symptom
with B-Detailed_description
internal I-Detailed_description
hemorrhage I-Detailed_description
at O
the O
right B-Biological_structure
hepatic I-Biological_structure
lobe I-Biological_structure
and O
ruptured B-Biological_structure
to I-Biological_structure
peritoneum I-Biological_structure
( O
Fig. O
1A O
) O
, O
so O
an O
emergency B-Detailed_description
hepatic B-Biological_structure
central I-Biological_structure
bisectionectomy B-Therapeutic_procedure
was O
done O
( O
Fig. O
2A O
) O
. O
The O
initial O
histological O
diagnosis O
was O
cHCC-CC B-Disease_disorder
with O
spindle B-Detailed_description
cell I-Detailed_description
metaplasia I-Detailed_description
of I-Detailed_description
cholangiocarcinoma I-Detailed_description
element I-Detailed_description
( O
Fig. O
2B O
) O
. O
The O
serum B-Diagnostic_procedure
AFP I-Diagnostic_procedure
was O
decreased B-Lab_value
to O
7.67 B-Lab_value
ng/mL I-Lab_value
at O
time O
of O
discharge B-Clinical_event
. O
Regarding O
as O
cHCC-CC B-Disease_disorder
, O
postoperative O
adjuvant B-Detailed_description
chemotherapy O
with O
tegafur/uracil O
( O
UFT O
) O
was O
administrated O
for O
3 O
months O
. O
3 B-Date
months I-Date
later I-Date
, O
follow-up B-Clinical_event
abdominal B-Biological_structure
CT B-Diagnostic_procedure
scanning O
showed O
previously O
unseen O
a O
5.5 O
cm O
sized O
left B-Biological_structure
subphrenic I-Biological_structure
mass B-Sign_symptom
with O
mild B-Severity
enhancement B-Sign_symptom
in O
delayed B-Detailed_description
image I-Detailed_description
( O
Fig. O
3A O
, O
B O
) O
and O
AFP B-Diagnostic_procedure
was O
increased B-Lab_value
to O
312.06 B-Lab_value
ng/mL I-Lab_value
. O
She O
underwent O
laparoscopic B-Detailed_description
splenectomy B-Therapeutic_procedure
with O
mass B-Therapeutic_procedure
excision I-Therapeutic_procedure
. O
On O
histologic B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
mesenchymal B-Diagnostic_procedure
elements I-Diagnostic_procedure
consisted O
of O
a O
proliferation B-Lab_value
of I-Lab_value
primitive-appearing I-Lab_value
mesenchymal I-Lab_value
spindle-shaped I-Lab_value
cells I-Lab_value
, O
intimately B-Detailed_description
admixed I-Detailed_description
with I-Detailed_description
the I-Detailed_description
epithelial I-Detailed_description
elements I-Detailed_description
in I-Detailed_description
a I-Detailed_description
highly I-Detailed_description
cellular I-Detailed_description
pattern I-Detailed_description
. O
Cytoplasm B-Diagnostic_procedure
was O
more B-Lab_value
abundant I-Lab_value
than I-Lab_value
that I-Lab_value
of I-Lab_value
mature I-Lab_value
fibroblasts I-Lab_value
, O
and O
the O
nucleus B-Diagnostic_procedure
was O
elongated O
and O
plump O
. O
These O
cells B-Lab_value
blended I-Lab_value
progressively I-Lab_value
with I-Lab_value
areas I-Lab_value
of I-Lab_value
less I-Lab_value
intense I-Lab_value
cellular I-Lab_value
mesenchymal I-Lab_value
proliferation I-Lab_value
, O
and O
with O
relatively B-Detailed_description
acellular I-Detailed_description
, I-Detailed_description
fibrous I-Detailed_description
septa I-Detailed_description
. O
Osteoid B-Diagnostic_procedure
was O
present B-Lab_value
either O
within B-Detailed_description
the I-Detailed_description
primitive I-Detailed_description
mesenchyme I-Detailed_description
, O
near B-Detailed_description
the I-Detailed_description
fibrous I-Detailed_description
septa I-Detailed_description
or I-Detailed_description
pseudocapsule I-Detailed_description
, O
or O
admixed B-Detailed_description
within I-Detailed_description
the I-Detailed_description
epithelial I-Detailed_description
elements I-Detailed_description
. O
Osteoid B-Diagnostic_procedure
foci I-Diagnostic_procedure
contained O
cells B-Lab_value
morphologically I-Lab_value
identical I-Lab_value
to I-Lab_value
osteoblasts I-Lab_value
( O
Fig. O
4A O
) O
. O
The O
immunohistochemistry B-Diagnostic_procedure
stains I-Diagnostic_procedure
showed O
expression B-Lab_value
of O
hepatocyte B-Diagnostic_procedure
, O
β-HCG B-Diagnostic_procedure
, O
AFP B-Diagnostic_procedure
, O
vimentin B-Diagnostic_procedure
, O
CK7 B-Diagnostic_procedure
, O
CK19 B-Diagnostic_procedure
, O
CD56 B-Diagnostic_procedure
and O
β-catenin B-Diagnostic_procedure
and O
negativity B-Lab_value
for O
CEA B-Diagnostic_procedure
. O
( O
Fig. O
4B O
, O
C O
, O
D O
, O
E O
, O
F O
, O
G O
) O
. O
Metastatic B-Detailed_description
hepatoblastoma B-Disease_disorder
was O
confirmed O
by O
histologic B-Diagnostic_procedure
examination I-Diagnostic_procedure
with O
immunohistochemistry B-Diagnostic_procedure
stains I-Diagnostic_procedure
, O
so O
immunohistochemistrically O
re-examination O
of O
previous O
surgical O
specimens O
was O
also O
confirmed O
as O
hepatoblastoma O
. O
Follow-up B-Clinical_event
abdominal B-Biological_structure
CT B-Diagnostic_procedure
scan O
performed O
1 B-Date
month I-Date
after I-Date
reoperation O
showed O
a O
newly B-Detailed_description
onset I-Detailed_description
1.7 O
cm O
sized O
subtle B-Detailed_description
enhancing I-Detailed_description
soft B-Detailed_description
tissue I-Detailed_description
mass B-Sign_symptom
in O
splenic B-Biological_structure
bed I-Biological_structure
, O
and O
positron B-Diagnostic_procedure
emission I-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
PET B-Diagnostic_procedure
) O
showed O
multiple B-Detailed_description
FDG B-Detailed_description
uptake B-Sign_symptom
( O
max B-Lab_value
SUV I-Lab_value
> I-Lab_value
3.80 I-Lab_value
) O
in O
left B-Detailed_description
upper I-Detailed_description
and O
lower B-Detailed_description
quadrant I-Detailed_description
area O
of O
abdomen B-Biological_structure
, O
paralumbar B-Biological_structure
area I-Biological_structure
including I-Biological_structure
right I-Biological_structure
subphrenic I-Biological_structure
area I-Biological_structure
( O
Fig. O
5A O
, O
B O
, O
C O
) O
. O
Follow-up B-Clinical_event
AFP B-Diagnostic_procedure
was O
162.69 B-Lab_value
ng/mL I-Lab_value
. O
Systemic B-Detailed_description
chemotherapy O
started O
with O
cisplatin O
( O
60 O
mg/m2 O
) O
, O
5-fluorourasil O
( O
5-FU O
) O
( O
600 O
mg/m2 O
) O
, O
vincristine O
( O
1.5 O
mg/m2 O
) O
and O
total O
3 O
cycles O
of O
chemotherapy O
were O
done O
every O
4 O
week O
. O
Entecavir O
0.5 O
mg O
was O
also O
started O
for O
chemoprophylaxis O
of O
CHB B-Disease_disorder
. O
After O
the O
3rd O
chemotherapy O
cycle O
, O
follow-up B-Clinical_event
abdominal B-Biological_structure
CT B-Diagnostic_procedure
and O
PET B-Diagnostic_procedure
scan O
showed O
progression O
of O
multiple B-Detailed_description
intraperitoneal B-Biological_structure
metastasis B-Sign_symptom
with O
large B-Severity
amount I-Severity
of O
intraperitoneal B-Biological_structure
fluid B-Sign_symptom
( O
Fig. O
6A O
, O
B O
) O
and O
follow-up B-Clinical_event
AFP B-Diagnostic_procedure
was O
further O
increased B-Lab_value
to O
254 B-Lab_value
ng/mL I-Lab_value
. O
So O
chemotherapy O
regimen O
was O
changed O
to O
carboplatin O
( O
350 B-Lab_value
mg/m2 I-Lab_value
) O
with O
doxorubicin O
( O
30 B-Lab_value
mg/m2 I-Lab_value
) O
every O
3 O
weeks O
. O
The O
patient O
experienced O
neutropenia B-Sign_symptom
after O
the O
new O
regimen O
, O
but O
recovered B-Sign_symptom
shortly O
after O
treatment O
with O
granulocyte O
colony-stimulating O
factor O
( O
G-CSF O
) O
. O
After O
second O
carboplatin O
with O
doxorubicin O
chemotherapy O
, O
follow-up B-Clinical_event
AFP B-Diagnostic_procedure
was O
increased B-Lab_value
1510.19 B-Lab_value
ng/mL I-Lab_value
, O
but O
abdominal B-Biological_structure
CT B-Diagnostic_procedure
scan O
showed O
that O
amount O
of O
ascites B-Sign_symptom
was O
decreased O
( O
Fig. O
7 O
) O
. O
Because O
of O
radiologic O
improvements O
, O
third O
and O
fourth O
chemotherapy O
were O
performed O
. O
After O
4th O
chemotherapy O
, O
follow-up B-Clinical_event
abdominal B-Biological_structure
CT B-Diagnostic_procedure
revealed O
progression O
of O
multiple B-Detailed_description
intraperitoneal B-Biological_structure
metastatic B-Detailed_description
masses B-Sign_symptom
, O
newly O
developed O
hepatic B-Biological_structure
metastasis B-Sign_symptom
and O
large B-Severity
amount I-Severity
of O
intraperitoneal B-Biological_structure
fluid B-Sign_symptom
( O
Fig. O
8 O
) O
. O
A O
diagnostic O
paracentesis B-Diagnostic_procedure
was O
performed O
and O
showed O
white B-Diagnostic_procedure
blood I-Diagnostic_procedure
cell I-Diagnostic_procedure
310/mm3 B-Lab_value
( O
poly B-Diagnostic_procedure
20 B-Lab_value
% I-Lab_value
, O
lymph B-Diagnostic_procedure
80 B-Lab_value
% I-Lab_value
) O
, O
protein B-Diagnostic_procedure
3.6 B-Lab_value
g/dL I-Lab_value
and O
albumin B-Diagnostic_procedure
2.3 B-Lab_value
g/dL I-Lab_value
on O
ascitic B-Diagnostic_procedure
fluid I-Diagnostic_procedure
analysis I-Diagnostic_procedure
. O
The O
serum B-Diagnostic_procedure
albumin I-Diagnostic_procedure
was O
3.1 B-Lab_value
g/dL I-Lab_value
and O
serum-ascites B-Diagnostic_procedure
albumin I-Diagnostic_procedure
gradient I-Diagnostic_procedure
( O
SAAG B-Diagnostic_procedure
) O
was O
0.8 B-Lab_value
g/dL I-Lab_value
. O
The O
AFB B-Diagnostic_procedure
stain I-Diagnostic_procedure
and I-Diagnostic_procedure
culture I-Diagnostic_procedure
were O
all O
negative B-Lab_value
in O
ascitic B-Detailed_description
fluid I-Detailed_description
. O
The O
AFP B-Diagnostic_procedure
was O
6881.93 B-Lab_value
ng/mL I-Lab_value
on O
serum B-Detailed_description
. O
Regarded O
as O
peritoneal B-Biological_structure
carcinomatosis B-Disease_disorder
, O
the O
patient O
underwent O
conservative B-Therapeutic_procedure
treatments I-Therapeutic_procedure
including O
the O
use O
of O
repeated B-Detailed_description
therapeutic B-Therapeutic_procedure
paracentesis I-Therapeutic_procedure
for O
1 O
month O
before O
death O
. O
A O
13 B-Age
year-old I-Age
boy B-Sex
presented B-Clinical_event
with O
a O
1 O
month O
history O
of O
intermittent B-Biological_structure
episodes O
of O
small B-Detailed_description
volume I-Detailed_description
epistaxis B-Sign_symptom
. O
There O
was O
no O
significant O
past O
medical O
, O
surgical O
or O
family O
history O
. O
Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
left B-Biological_structure
palatal I-Biological_structure
fleshy B-Detailed_description
mass B-Sign_symptom
centered O
at O
left B-Biological_structure
posterior I-Biological_structure
molars I-Biological_structure
. O
A O
nasoendoscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
demonstrated O
a O
large B-Severity
swelling B-Sign_symptom
on O
the O
floor B-Biological_structure
of I-Biological_structure
left I-Biological_structure
anterior I-Biological_structure
nasal I-Biological_structure
space I-Biological_structure
, O
involving O
the O
left B-Biological_structure
inferior I-Biological_structure
meatus I-Biological_structure
and O
abutting O
the O
inferior B-Biological_structure
turbinate I-Biological_structure
. O
Computed B-Diagnostic_procedure
Tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
of O
the O
paranasal B-Biological_structure
sinuses I-Biological_structure
showed O
a O
lobulated B-Detailed_description
, O
expansile B-Detailed_description
lytic B-Detailed_description
lesion B-Sign_symptom
of O
left B-Biological_structure
maxilla I-Biological_structure
[ O
Fig O
1 O
] O
with O
a O
lucent B-Detailed_description
center I-Detailed_description
and O
peripheral B-Detailed_description
calcifications I-Detailed_description
. O
The O
lesion O
was O
associated O
with O
a O
large B-Detailed_description
soft I-Detailed_description
tissue I-Detailed_description
component I-Detailed_description
that O
demonstrated O
mild B-Severity
heterogeneous B-Detailed_description
contrast B-Sign_symptom
enhancement I-Sign_symptom
. O
The O
lesion O
was O
centered O
at O
the O
left B-Biological_structure
maxillary I-Biological_structure
alveolus I-Biological_structure
, O
involving O
the O
left B-Biological_structure
hard I-Biological_structure
palate I-Biological_structure
, O
inferior B-Biological_structure
part I-Biological_structure
of I-Biological_structure
the I-Biological_structure
anterior I-Biological_structure
left I-Biological_structure
maxillary I-Biological_structure
wall I-Biological_structure
and O
medial B-Biological_structure
left I-Biological_structure
maxillary I-Biological_structure
wall I-Biological_structure
. O
The O
lesion O
also O
involved O
the O
roots B-Biological_structure
of I-Biological_structure
the I-Biological_structure
left I-Biological_structure
maxillary I-Biological_structure
molars I-Biological_structure
and I-Biological_structure
pre-molars I-Biological_structure
and O
was O
abutting O
the O
left B-Biological_structure
orbital I-Biological_structure
floor I-Biological_structure
, O
with O
no O
gross O
orbital B-Biological_structure
invasion B-Sign_symptom
. O
The O
patient O
subsequently O
underwent O
18-FDG B-Diagnostic_procedure
PET-CT I-Diagnostic_procedure
study I-Diagnostic_procedure
. O
The O
mass O
centered O
in O
left B-Biological_structure
maxilla I-Biological_structure
was O
hypermetabolic B-Detailed_description
, O
with O
index B-Lab_value
SUVmax I-Lab_value
9.7 I-Lab_value
[ O
Fig O
2 O
] O
. O
There O
was O
no O
FDG-avid B-Detailed_description
metastatic B-Disease_disorder
disease I-Disease_disorder
. O
A O
trans-oral B-Detailed_description
incisional B-Diagnostic_procedure
biopsy I-Diagnostic_procedure
of O
the O
left B-Biological_structure
palatal I-Biological_structure
mass B-Sign_symptom
was O
performed O
and O
was O
suggestive O
of O
a O
preliminary O
diagnosis O
of O
mesenchymal B-Disease_disorder
chondrosarcoma I-Disease_disorder
, O
as O
evidenced O
by O
a O
biphasic B-Detailed_description
pattern I-Detailed_description
featuring O
sheets B-Detailed_description
of I-Detailed_description
small I-Detailed_description
round I-Detailed_description
cells I-Detailed_description
with O
hemangiopericytoma-like B-Detailed_description
vascular I-Detailed_description
pattern I-Detailed_description
and O
mature B-Detailed_description
cartilaginous I-Detailed_description
islands I-Detailed_description
. O
The O
patient O
underwent O
left B-Detailed_description
subtotal I-Detailed_description
maxillectomy B-Therapeutic_procedure
via O
lateral B-Detailed_description
rhinotomy B-Therapeutic_procedure
and O
translabial B-Detailed_description
approach I-Detailed_description
. O
The O
final O
histology B-Diagnostic_procedure
was O
conclusive O
of O
a O
5 O
cm O
high-grade B-Lab_value
( O
Grade B-Lab_value
3 I-Lab_value
) O
mesenchymal B-Disease_disorder
chondrosarcoma I-Disease_disorder
. O
One O
of O
the O
resection B-Biological_structure
margins I-Biological_structure
was O
positive O
for O
tumor B-Sign_symptom
involvement I-Sign_symptom
and O
the O
patient O
was O
planned O
for O
adjuvant B-Detailed_description
chemotherapy O
. O
Our O
patient O
was O
a O
50-year B-Age
old I-Age
man B-Sex
with O
bicuspid B-Detailed_description
aortic B-Sign_symptom
valve I-Sign_symptom
insufficiency I-Sign_symptom
and O
ascending B-Detailed_description
aorta B-Sign_symptom
dilatation I-Sign_symptom
. O
He O
had O
undergone O
a O
free-hand B-Detailed_description
aortic B-Biological_structure
homograft B-Therapeutic_procedure
implantation I-Therapeutic_procedure
with O
replacement B-Therapeutic_procedure
of O
the O
non-coronary B-Biological_structure
sinus I-Biological_structure
using O
a O
24-mm B-Detailed_description
homograft I-Detailed_description
in O
2006 B-Date
( O
at O
the O
age O
of O
41 O
) O
. O
Follow-up B-Clinical_event
evaluations O
were O
performed O
every O
6 O
months O
and O
showed O
mild B-Severity
aortic B-Sign_symptom
valve I-Sign_symptom
insufficiency I-Sign_symptom
. O
After O
8 O
years O
of O
follow-up B-Clinical_event
, O
the O
patient O
presented B-Clinical_event
to O
hospital B-Nonbiological_location
with O
fever B-Sign_symptom
and O
the O
echocardiography B-Diagnostic_procedure
showed O
severe B-Severity
aortic B-Sign_symptom
insufficiency I-Sign_symptom
due O
to O
a O
rupture B-Sign_symptom
of O
one B-Biological_structure
of I-Biological_structure
the I-Biological_structure
cusps I-Biological_structure
of I-Biological_structure
the I-Biological_structure
homograft I-Biological_structure
, O
worsening B-Lab_value
of O
cardiac B-Diagnostic_procedure
contractility I-Diagnostic_procedure
with O
left B-Diagnostic_procedure
ventricular I-Diagnostic_procedure
ejection I-Diagnostic_procedure
fraction I-Diagnostic_procedure
( O
LVEF B-Diagnostic_procedure
) O
depression B-Lab_value
( O
40 B-Lab_value
– I-Lab_value
45 I-Lab_value
% I-Lab_value
) O
and O
dilatation B-Sign_symptom
of I-Sign_symptom
the I-Sign_symptom
left I-Sign_symptom
ventricle I-Sign_symptom
( O
telediastolic/telesystolic B-Lab_value
diameters I-Lab_value
60/42 I-Lab_value
mm I-Lab_value
, O
respectively O
) O
. O
The O
patient O
presented O
orthopnoea B-Sign_symptom
and O
hypotension B-Sign_symptom
, O
which O
needed O
infusion O
of O
dopamine O
and O
diuretics O
. O
Computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
scan O
showed O
calcifications B-Sign_symptom
on O
the O
homograft B-Biological_structure
, O
pleural B-Sign_symptom
effusions I-Sign_symptom
and O
no O
signs O
of O
pericardial B-Sign_symptom
effusion I-Sign_symptom
( O
Fig. O
1 O
) O
. O
Since O
the O
Dukes B-Diagnostic_procedure
criteria I-Diagnostic_procedure
for I-Diagnostic_procedure
endocarditis I-Diagnostic_procedure
were O
not B-Lab_value
satisfied I-Lab_value
, O
the O
final O
diagnosis O
was O
an O
early O
structural B-Disease_disorder
deterioration I-Disease_disorder
of O
the O
homograft B-Biological_structure
, O
due O
to O
a O
severe B-Severity
calcification B-Sign_symptom
process O
. O
The O
operation B-Therapeutic_procedure
was O
performed O
through O
median B-Detailed_description
resternotomy B-Therapeutic_procedure
and O
with O
standard B-Detailed_description
aorta-right B-Biological_structure
atrium I-Biological_structure
central B-Therapeutic_procedure
cannulation I-Therapeutic_procedure
for O
the O
extracorporeal O
circulation O
. O
The O
leaflets B-Biological_structure
and O
the O
annulus B-Biological_structure
of O
the O
homograft B-Biological_structure
presented O
severe B-Severity
calcifications B-Sign_symptom
and O
no O
signs O
of O
endocarditis B-Disease_disorder
were O
found O
. O
An O
Edwards B-Detailed_description
Intuity I-Detailed_description
bioprosthesis B-Therapeutic_procedure
( O
21 O
mm O
) O
was O
then O
implanted B-Therapeutic_procedure
( O
Fig. O
2 O
) O
. O
The O
cross-clamping B-Therapeutic_procedure
time O
was O
41 O
min O
, O
and O
the O
cardiopulmonary B-Therapeutic_procedure
bypass I-Therapeutic_procedure
time O
was O
64 O
min O
. O
The O
patient O
required O
dopamine O
and O
adrenaline O
at O
low O
doses O
for O
bypass O
weaning O
. O
No O
complications B-Sign_symptom
occurred O
during O
the O
postoperative B-Therapeutic_procedure
period I-Therapeutic_procedure
. O
Echocardiography B-Diagnostic_procedure
before O
the O
discharge B-Clinical_event
showed O
the O
absence O
of O
paravalvular B-Sign_symptom
leaks I-Sign_symptom
, O
a O
peak/mean B-Diagnostic_procedure
aortic I-Diagnostic_procedure
gradient I-Diagnostic_procedure
of O
34/20 B-Lab_value
mmHg I-Lab_value
and O
an O
LVEF B-Diagnostic_procedure
of O
33 B-Lab_value
% I-Lab_value
. O
Follow-up O
echocardiography B-Diagnostic_procedure
after B-Date
3 I-Date
months I-Date
from O
the O
operation O
showed O
neither O
leaks B-Sign_symptom
nor O
malfunctions B-Sign_symptom
of O
the O
Edwards B-Detailed_description
Intuity I-Detailed_description
prosthesis B-Biological_structure
, O
a O
peak/mean B-Diagnostic_procedure
gradient I-Diagnostic_procedure
of O
38/22 B-Lab_value
mmHg I-Lab_value
and O
initial B-Lab_value
recovery I-Lab_value
of O
the O
LVEF B-Diagnostic_procedure
( O
valued O
47 B-Lab_value
% I-Lab_value
) O
. O
Patient O
was O
asymptomatic B-Sign_symptom
again O
. O
A O
24-year-old B-Age
Azeri O
male B-Sex
presented B-Clinical_event
with O
a O
chief O
complaint O
of O
blurred B-Sign_symptom
vision I-Sign_symptom
in O
both B-Biological_structure
eyes I-Biological_structure
. O
He O
was O
diagnosed O
with O
achondroplasia O
in O
early O
childhood O
. O
He O
was O
born O
at O
term O
with O
normal O
birth O
weight O
. O
There O
was O
no O
history O
of O
hereditary O
ocular O
or O
systemic O
disease O
. O
This O
patient O
had O
characteristic B-Sign_symptom
features I-Sign_symptom
of I-Sign_symptom
achondroplasia I-Sign_symptom
( O
i.e. O
, O
short O
stature O
, O
lumbar O
lordosis O
, O
short O
proximal O
long O
bones O
, O
large O
hands O
, O
frontal O
bossing O
, O
and O
flat O
nasal O
bridge O
) O
[ O
Figure O
1 O
] O
. O
His O
height O
was O
108 O
cm O
. O
Best O
corrected B-Detailed_description
visual B-Diagnostic_procedure
acuity I-Diagnostic_procedure
was O
20/70 B-Lab_value
in O
the O
right B-Biological_structure
eye I-Biological_structure
with O
− B-Lab_value
0.75 I-Lab_value
+ I-Lab_value
1.25 I-Lab_value
× I-Lab_value
60 I-Lab_value
° I-Lab_value
and O
20/70 B-Lab_value
in O
the O
left B-Biological_structure
eye I-Biological_structure
with O
OS B-Biological_structure
: O
+0.25 B-Lab_value
+ I-Lab_value
0.50 I-Lab_value
× I-Lab_value
130 I-Lab_value
° I-Lab_value
. O
Pupils B-Biological_structure
were O
equal B-Detailed_description
in I-Detailed_description
size I-Detailed_description
, O
round B-Detailed_description
and O
reactive B-Detailed_description
to I-Detailed_description
light I-Detailed_description
with O
no O
reverse B-Sign_symptom
afferent I-Sign_symptom
pupillary I-Sign_symptom
defect I-Sign_symptom
. O
Ocular B-Diagnostic_procedure
motility I-Diagnostic_procedure
was O
normal B-Lab_value
in O
both B-Biological_structure
eyes I-Biological_structure
and O
slit B-Diagnostic_procedure
lamp I-Diagnostic_procedure
examination I-Diagnostic_procedure
was O
unremarkable B-Lab_value
. O
The O
intraocular B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
12 B-Lab_value
mm I-Lab_value
Hg I-Lab_value
by O
Goldmann B-Detailed_description
applanation I-Detailed_description
tonometry I-Detailed_description
. O
Central B-Diagnostic_procedure
corneal I-Diagnostic_procedure
thickness I-Diagnostic_procedure
values I-Diagnostic_procedure
of O
the O
right B-Biological_structure
and I-Biological_structure
left I-Biological_structure
eyes I-Biological_structure
were O
, O
561 B-Lab_value
and I-Lab_value
557 I-Lab_value
μ I-Lab_value
, O
respectively O
. O
Dilated B-Diagnostic_procedure
fundus I-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
a O
well-demarcated B-Detailed_description
circular O
macular B-Biological_structure
lesion B-Sign_symptom
in O
both B-Biological_structure
eyes I-Biological_structure
. O
In O
the O
right B-Biological_structure
eye I-Biological_structure
, O
this O
lesion B-Sign_symptom
was O
approximately O
2.5 O
disc O
diameters O
( O
DD O
) O
in O
width O
and O
2.7 O
DD O
in O
length O
. O
In O
the O
left B-Biological_structure
eye I-Biological_structure
, O
this O
lesion B-Sign_symptom
was O
approximately O
2.5 O
DD O
in O
width O
and O
2.8 O
DD O
in O
length O
. O
The O
border B-Detailed_description
of O
the O
lesions B-Sign_symptom
was O
pigmented B-Detailed_description
. O
Underlying O
choroidal B-Biological_structure
and O
overlying O
retinal B-Biological_structure
vasculature B-Biological_structure
appeared O
normal B-Lab_value
. O
In O
addition O
, O
a O
stalk B-Sign_symptom
of I-Sign_symptom
tissue I-Sign_symptom
emanated O
from B-Biological_structure
the I-Biological_structure
optic I-Biological_structure
disc I-Biological_structure
and O
coursed O
into B-Biological_structure
the I-Biological_structure
vitreous I-Biological_structure
[ O
Figure O
2 O
] O
. O
Fluorescein B-Detailed_description
angiography B-Diagnostic_procedure
of O
the O
posterior B-Biological_structure
segment I-Biological_structure
and O
optical B-Diagnostic_procedure
coherence I-Diagnostic_procedure
tomography I-Diagnostic_procedure
of O
the O
optic B-Biological_structure
nerve I-Biological_structure
head I-Biological_structure
( O
Stratus O
; O
Carl O
Zeiss O
GmbH O
, O
Jena O
, O
Germany O
) O
were O
performed O
[ O
Figures O
[ O
Figures3 O
and O
4 O
] O
. O
Due O
to O
the O
background O
maculopathy O
, O
the O
patient O
could O
not O
appropriately O
fixate O
on O
the O
target O
during O
image O
acquisition O
resulting O
in O
slightly O
decentered O
fluorescein O
angiography O
images O
[ O
Figure O
3 O
] O
. O
A O
65-year-old B-Age
man B-Sex
was O
admitted B-Clinical_event
to O
the O
China-Japan B-Nonbiological_location
Friendship I-Nonbiological_location
hospital I-Nonbiological_location
with O
a O
chief O
complaint O
of O
progressive B-Detailed_description
dysphagia B-Sign_symptom
for O
3 O
mo O
. O
He O
also O
complained O
of O
a O
drastic B-Severity
weight B-Sign_symptom
loss I-Sign_symptom
of O
8 B-Lab_value
kg I-Lab_value
in O
the O
past O
2 O
mo O
. O
He O
denied O
a O
history O
of O
smoking O
, O
alcohol O
intake O
and O
substance O
abuse O
, O
but O
had O
a O
chronic B-Detailed_description
atrophic B-Detailed_description
gastritis O
for O
nearly O
10 O
years O
. O
Also O
, O
there O
was O
no O
family O
history O
of O
genetic O
defect O
or O
malignancy O
. O
Physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
no B-Lab_value
palpable I-Lab_value
findings I-Lab_value
. O
Admission O
blood B-Diagnostic_procedure
test I-Diagnostic_procedure
showed O
a O
slight B-Lab_value
decrease I-Lab_value
in O
hemoglobin B-Diagnostic_procedure
( O
106 B-Lab_value
g/L I-Lab_value
) O
. O
Upper B-Biological_structure
gastrointestinal I-Biological_structure
( O
GI B-Biological_structure
) O
examination B-Diagnostic_procedure
using O
barium B-Detailed_description
contrasts I-Detailed_description
showed O
a O
large B-Severity
tumor B-Sign_symptom
blocking B-Sign_symptom
the O
esophago-gastric B-Biological_structure
junction I-Biological_structure
( O
Figure O
1 O
) O
. O
Computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
( O
CT B-Diagnostic_procedure
) O
scan O
revealed O
a O
soft O
mass B-Sign_symptom
in O
the O
esophago-gastric B-Biological_structure
junction I-Biological_structure
with O
lymph B-Biological_structure
node I-Biological_structure
metastasis B-Sign_symptom
in O
the O
lesser B-Biological_structure
curvature I-Biological_structure
of I-Biological_structure
the I-Biological_structure
stomach I-Biological_structure
( O
Figure O
2 O
) O
. O
Endoscopic B-Diagnostic_procedure
examination I-Diagnostic_procedure
showed O
a O
black O
spot B-Sign_symptom
in O
the O
lower B-Biological_structure
esophagus I-Biological_structure
and O
a O
bulky B-Detailed_description
black O
mass B-Sign_symptom
blocking B-Sign_symptom
the O
esophago-gastric B-Biological_structure
junction I-Biological_structure
, O
as O
well O
as O
two B-Detailed_description
black O
crater-like O
ulcers B-Sign_symptom
in O
the O
fundus B-Biological_structure
of I-Biological_structure
the I-Biological_structure
stomach I-Biological_structure
( O
Figure O
3 O
) O
. O
Biopsy B-Diagnostic_procedure
specimens O
taken O
from O
the O
tumor B-Sign_symptom
were O
identified O
as O
poorly B-Detailed_description
differentiated I-Detailed_description
adenocarcinoma B-Disease_disorder
. O
Preoperative O
nutrition B-Diagnostic_procedure
status I-Diagnostic_procedure
of O
this O
case O
was O
scored O
2 B-Lab_value
based O
on O
the O
Nutrition B-Detailed_description
Risk I-Detailed_description
Screening I-Detailed_description
2002 I-Detailed_description
( O
NRS O
2002 O
) O
[ O
6 O
] O
. O
Because O
of O
the O
obstructive O
symptom O
caused O
by O
the O
tumor O
, O
a O
debulking B-Therapeutic_procedure
surgery I-Therapeutic_procedure
of O
distal B-Detailed_description
esophagectomy B-Therapeutic_procedure
and O
proximal B-Detailed_description
gastrectomy B-Therapeutic_procedure
was O
performed O
. O
Esophagogastric B-Biological_structure
anastomosis B-Therapeutic_procedure
and O
reconstruction B-Therapeutic_procedure
was O
then O
completed O
with O
stapling B-Therapeutic_procedure
device I-Therapeutic_procedure
. O
Intraoperatively O
, O
the O
tumor B-Sign_symptom
was O
found O
located O
at O
the O
esophago-gastric B-Biological_structure
junction I-Biological_structure
and O
the O
tumor O
infiltrated B-Sign_symptom
the O
whole B-Biological_structure
layer I-Biological_structure
with O
lymph B-Biological_structure
node I-Biological_structure
metastasis B-Sign_symptom
at O
station B-Biological_structure
four I-Biological_structure
. O
No O
ascites B-Sign_symptom
or O
dissemination B-Sign_symptom
of I-Sign_symptom
the I-Sign_symptom
tumor I-Sign_symptom
was O
observed O
in O
the O
peritoneal B-Biological_structure
cavity I-Biological_structure
. O
The O
tumor B-Sign_symptom
measured O
3 O
cm O
× O
6 O
cm O
in O
size O
with O
black O
pigmentation O
( O
Figure O
4 O
) O
. O
There O
were O
several B-Detailed_description
pigmented O
satellite B-Detailed_description
nodules B-Sign_symptom
beside O
the O
main O
tumor O
lesion O
, O
the O
largest O
one O
being O
1 O
cm O
× O
1 O
cm O
in O
diameter O
. O
Moreover O
, O
two O
ulceration B-Detailed_description
lesions B-Sign_symptom
were O
found O
at O
the O
fundus B-Biological_structure
of I-Biological_structure
the I-Biological_structure
stomach I-Biological_structure
. O
Microscopically B-Diagnostic_procedure
, O
the O
excised O
tumor B-Biological_structure
tissue I-Biological_structure
was O
composed O
of O
non-organized B-Lab_value
and O
pleomorphic B-Lab_value
cells B-Diagnostic_procedure
exhibiting O
atypical B-Lab_value
nuclei B-Diagnostic_procedure
, O
and O
abundant B-Lab_value
melanin B-Diagnostic_procedure
granules I-Diagnostic_procedure
( O
Figure O
5 O
) O
. O
Pathological B-Diagnostic_procedure
examination I-Diagnostic_procedure
identified O
this O
case O
at O
a O
stage B-Diagnostic_procedure
of O
IVA B-Lab_value
( O
T4aN1M0 B-Lab_value
) O
. O
Immunohistochemical B-Diagnostic_procedure
staining I-Diagnostic_procedure
showed O
that O
the O
tumor O
was O
positive B-Lab_value
for O
S-100 B-Diagnostic_procedure
, O
HMB-45 B-Diagnostic_procedure
, O
mclean-A B-Diagnostic_procedure
and O
Vimentin B-Diagnostic_procedure
, O
but O
negative B-Lab_value
for O
cytokeratin B-Diagnostic_procedure
7 I-Diagnostic_procedure
and O
cytokeratin B-Diagnostic_procedure
20 I-Diagnostic_procedure
( O
Figure O
6 O
) O
. O
Based O
on O
these O
results O
, O
a O
diagnosis O
of O
primary B-Detailed_description
advanced B-Severity
esophago-gastric B-Detailed_description
melanoma B-Disease_disorder
was O
established O
. O
The O
postoperative B-Therapeutic_procedure
course I-Therapeutic_procedure
was O
smooth B-Lab_value
and O
without O
complications B-Sign_symptom
. O
The O
patient O
gradually O
recovered B-Sign_symptom
and O
was O
discharged B-Clinical_event
14 B-Date
d I-Date
after I-Date
surgery O
. O
As O
the O
patient O
denied O
a O
postoperative O
adjuvant O
therapy O
, O
abdominal B-Biological_structure
recurrence B-Sign_symptom
and O
hepatic B-Biological_structure
metastases B-Sign_symptom
were O
found O
within B-Date
one I-Date
month I-Date
by O
a O
postoperative O
follow-up B-Clinical_event
CT B-Diagnostic_procedure
. O
No O
other B-Therapeutic_procedure
effective I-Therapeutic_procedure
treatment I-Therapeutic_procedure
was O
administered O
afterwards O
. O
The O
patient O
died O
of O
diffuse B-Detailed_description
metastatic B-Disease_disorder
disease I-Disease_disorder
2 B-Date
mo I-Date
later I-Date
. O
A O
70-year-old B-Age
male B-Sex
was O
admitted B-Clinical_event
to O
our O
hospital O
for O
perioperative B-Detailed_description
cardiac B-Diagnostic_procedure
evaluation I-Diagnostic_procedure
of O
abdominal B-Biological_structure
aortic I-Biological_structure
aneurysm B-Disease_disorder
. O
The O
patient O
had O
undergone O
coronary B-Therapeutic_procedure
artery I-Therapeutic_procedure
bypass I-Therapeutic_procedure
grafting I-Therapeutic_procedure
( O
CABG B-Therapeutic_procedure
) O
for O
severe B-Severity
stenosis B-Sign_symptom
of O
the O
left B-Biological_structure
main I-Biological_structure
coronary I-Biological_structure
artery I-Biological_structure
( O
LMCA B-Biological_structure
) O
4 B-Date
years I-Date
before I-Date
, O
which O
consisted O
of O
the O
right B-Biological_structure
internal I-Biological_structure
thoracic I-Biological_structure
artery I-Biological_structure
( O
RITA B-Biological_structure
) O
to O
the O
left B-Biological_structure
anterior I-Biological_structure
descending I-Biological_structure
artery I-Biological_structure
( O
LAD B-Biological_structure
) O
and O
saphenous B-Therapeutic_procedure
vein I-Therapeutic_procedure
graft I-Therapeutic_procedure
( O
SVG B-Therapeutic_procedure
) O
to O
the O
left B-Biological_structure
circumflex I-Biological_structure
artery I-Biological_structure
( O
LCX B-Biological_structure
) O
. O
Due O
to O
continual O
growth O
of O
the O
abdominal B-Biological_structure
aortic I-Biological_structure
aneurysm B-Disease_disorder
over O
the O
years O
, O
surgery B-Therapeutic_procedure
was O
indicated O
. O
Left B-Biological_structure
coronary I-Biological_structure
angiogram B-Diagnostic_procedure
showed O
90 B-Lab_value
% I-Lab_value
stenosis B-Sign_symptom
of O
the O
LMCA B-Biological_structure
and O
total B-Severity
occlusion B-Sign_symptom
of O
both B-Detailed_description
grafts O
. O
PCI B-Therapeutic_procedure
was O
performed O
for O
LMCA B-Biological_structure
stenosis B-Sign_symptom
( O
Fig. O
1 O
) O
. O
A O
7-Fr B-Detailed_description
sheath B-Therapeutic_procedure
was O
inserted O
into O
the O
right B-Biological_structure
femoral I-Biological_structure
artery I-Biological_structure
, O
and O
a O
CLS4 B-Detailed_description
guiding B-Detailed_description
catheter B-Therapeutic_procedure
( O
Boston B-Detailed_description
Scientific I-Detailed_description
, I-Detailed_description
Natick I-Detailed_description
, I-Detailed_description
MA I-Detailed_description
, I-Detailed_description
USA I-Detailed_description
) O
was O
engaged O
into O
the O
left B-Biological_structure
coronary I-Biological_structure
artery I-Biological_structure
( O
LCA B-Biological_structure
) O
ostium B-Biological_structure
. O
A O
guidewire B-Therapeutic_procedure
( O
SION B-Detailed_description
Blue I-Detailed_description
, O
Asahi B-Detailed_description
Intecc I-Detailed_description
, I-Detailed_description
Aichi I-Detailed_description
, I-Detailed_description
Japan I-Detailed_description
) O
was O
inserted O
into O
the O
distal B-Biological_structure
LAD I-Biological_structure
, O
and O
another O
guidewire B-Therapeutic_procedure
( O
Hi-Torque B-Detailed_description
Pilot I-Detailed_description
50 I-Detailed_description
, O
Abbott B-Detailed_description
Vascular I-Detailed_description
, I-Detailed_description
Santa I-Detailed_description
Clara I-Detailed_description
, I-Detailed_description
California I-Detailed_description
, I-Detailed_description
USA I-Detailed_description
) O
was O
inserted O
into O
the O
distal B-Biological_structure
LCX I-Biological_structure
. O
Intravascular B-Diagnostic_procedure
ultrasound I-Diagnostic_procedure
( O
IVUS B-Diagnostic_procedure
) O
( O
Intra-focus B-Detailed_description
WR I-Detailed_description
, O
Terumo B-Detailed_description
Corp I-Detailed_description
, I-Detailed_description
Tokyo I-Detailed_description
, I-Detailed_description
Japan I-Detailed_description
) O
demonstrated O
heavy B-Severity
circumferential B-Detailed_description
calcification B-Sign_symptom
in O
the O
LMCA B-Biological_structure
lesion B-Sign_symptom
. O
After O
a O
4.0 B-Detailed_description
× I-Detailed_description
15-mm I-Detailed_description
Quantum B-Detailed_description
Maverick I-Detailed_description
balloon B-Detailed_description
catheter B-Therapeutic_procedure
( O
Boston B-Detailed_description
Scientific I-Detailed_description
) O
was O
inflated O
in O
the O
lesion B-Sign_symptom
, O
LCA B-Biological_structure
angiogram B-Diagnostic_procedure
revealed O
a O
large B-Severity
dissection B-Sign_symptom
( O
Fig. O
2 O
) O
. O
A O
4.0 B-Detailed_description
× I-Detailed_description
28-mm I-Detailed_description
Multi-Link B-Detailed_description
Vision I-Detailed_description
stent B-Therapeutic_procedure
( O
Abbott B-Detailed_description
Vascular I-Detailed_description
) O
was O
immediately O
deployed O
. O
Angiographic B-Diagnostic_procedure
image O
of O
the O
residual B-Detailed_description
dissection B-Sign_symptom
disappeared O
and O
the O
stent B-Therapeutic_procedure
was O
dilated O
by O
a O
5.0 B-Detailed_description
× I-Detailed_description
15-mm I-Detailed_description
Quantum B-Detailed_description
Maverick I-Detailed_description
balloon B-Therapeutic_procedure
catheter I-Therapeutic_procedure
. O
The O
absence O
of O
residual B-Detailed_description
dissection B-Sign_symptom
was O
confirmed O
by O
angiography B-Diagnostic_procedure
after O
stent B-Therapeutic_procedure
implantation O
. O
Next O
, O
LMCA-LAD B-Biological_structure
and O
LMCA-LCX B-Biological_structure
kissing B-Detailed_description
balloon I-Detailed_description
angioplasty B-Therapeutic_procedure
was O
initiated O
using O
a O
4.0 B-Detailed_description
× I-Detailed_description
28-mm I-Detailed_description
stent B-Detailed_description
delivery I-Detailed_description
balloon B-Therapeutic_procedure
in O
the O
LAD B-Biological_structure
and O
a O
3.0 B-Detailed_description
mm I-Detailed_description
× I-Detailed_description
15-mm I-Detailed_description
Ikazuchi B-Detailed_description
balloon B-Therapeutic_procedure
( O
Kaneka B-Detailed_description
Medics I-Detailed_description
, I-Detailed_description
Tokyo I-Detailed_description
, I-Detailed_description
Japan I-Detailed_description
) O
in O
the O
LCX B-Biological_structure
. O
The O
final O
angiographic B-Diagnostic_procedure
imaging O
showed O
optimal B-Lab_value
results B-Diagnostic_procedure
, O
and O
IVUS B-Diagnostic_procedure
imaging O
of O
the O
lesion B-Sign_symptom
showed O
completely B-Lab_value
sealing B-Diagnostic_procedure
by O
the O
stent B-Therapeutic_procedure
( O
Fig. O
3 O
) O
. O
A O
large B-Severity
hematoma B-Sign_symptom
at O
the O
femoral B-Biological_structure
puncture I-Biological_structure
site I-Biological_structure
and O
local B-Detailed_description
bleeding B-Sign_symptom
was O
observed O
after O
removal O
of O
the O
femoral B-Therapeutic_procedure
sheath I-Therapeutic_procedure
and O
manual B-Therapeutic_procedure
compression I-Therapeutic_procedure
was O
applied O
for O
haemostasis B-Therapeutic_procedure
. O
The O
hematoma B-Sign_symptom
did O
not O
appear O
to O
have O
spread O
the B-Date
next I-Date
day I-Date
and O
the O
patient O
was O
discharged B-Clinical_event
from O
the O
hospital B-Nonbiological_location
on O
the O
fifth B-Date
day I-Date
after I-Date
PCI B-Therapeutic_procedure
. O
Unexpectedly O
, O
the O
patient O
was O
admitted B-Clinical_event
to O
our O
emergency B-Nonbiological_location
room I-Nonbiological_location
with O
new-onset O
chest B-Biological_structure
pain B-Sign_symptom
and O
dyspnoea B-Sign_symptom
the O
next B-Date
day I-Date
after I-Date
the O
discharge B-Clinical_event
. O
His O
vital B-Diagnostic_procedure
signs I-Diagnostic_procedure
indicated O
cardiogenic B-Sign_symptom
shock I-Sign_symptom
. O
Electrocardiogram B-Diagnostic_procedure
showed O
ST B-Sign_symptom
elevation I-Sign_symptom
in O
leads B-Diagnostic_procedure
V1-V3 I-Diagnostic_procedure
. O
Although O
echocardiography B-Diagnostic_procedure
could O
not O
detect O
left B-Biological_structure
ventricular I-Biological_structure
asynergy B-Sign_symptom
, O
a O
large O
mass B-Sign_symptom
on O
the O
outflow B-Biological_structure
tract I-Biological_structure
of I-Biological_structure
right I-Biological_structure
ventricular I-Biological_structure
chamber I-Biological_structure
was O
observed O
( O
Fig. O
4 O
) O
. O
Contrast-enhanced B-Detailed_description
computed B-Diagnostic_procedure
tomography I-Diagnostic_procedure
showed O
a O
40-mm O
hematoma B-Sign_symptom
compressing B-Sign_symptom
the O
main B-Biological_structure
pulmonary I-Biological_structure
artery I-Biological_structure
trunk I-Biological_structure
and O
the O
right B-Biological_structure
ventricle I-Biological_structure
( O
Fig. O
5 O
) O
. O
During O
examination B-Diagnostic_procedure
, O
the O
patient O
suffered O
sudden B-Detailed_description
cardiopulmonary B-Disease_disorder
arrest I-Disease_disorder
. O
He O
received O
immediate B-Detailed_description
cardiopulmonary B-Therapeutic_procedure
resuscitation I-Therapeutic_procedure
and O
returned O
to O
spontaneous B-Sign_symptom
circulation I-Sign_symptom
after O
the O
insertion O
of O
a O
percutaneous B-Detailed_description
cardiopulmonary B-Therapeutic_procedure
support I-Therapeutic_procedure
device I-Therapeutic_procedure
. O
The O
patient O
underwent O
emergent B-Detailed_description
surgery B-Therapeutic_procedure
for O
the O
removal O
of O
the O
hematoma B-Sign_symptom
after O
informed O
consent O
was O
obtained O
from O
the O
patient O
's O
family O
. O
During O
surgery B-Therapeutic_procedure
, O
large B-Severity
, O
dark O
red O
clots B-Sign_symptom
between O
the O
pulmonary B-Biological_structure
artery I-Biological_structure
trunk I-Biological_structure
and O
aorta B-Biological_structure
were O
observed O
. O
The O
suspected O
origin O
of O
the O
epicardial B-Biological_structure
hematoma B-Sign_symptom
was O
blood B-Sign_symptom
oozing I-Sign_symptom
from O
the O
LMCA B-Biological_structure
stent I-Biological_structure
site I-Biological_structure
. O
Despite O
successful O
surgical B-Therapeutic_procedure
repair I-Therapeutic_procedure
, O
the O
patient O
died O
from O
aortic B-Disease_disorder
rupture I-Disease_disorder
induced O
by O
external B-Therapeutic_procedure
cardiac I-Therapeutic_procedure
massage I-Therapeutic_procedure
. O
An O
82-year-old B-Age
woman B-Sex
was O
transferred B-Clinical_event
to O
our O
hospital B-Nonbiological_location
because O
of O
dyspnea B-Sign_symptom
and O
massive B-Severity
hemoptysis B-Sign_symptom
. O
The O
patient O
had O
a O
history O
of O
bronchial O
asthma O
that O
was O
well-controlled O
with O
bronchodilator O
medications O
. O
She O
had O
no O
history O
of O
tuberculosis O
, O
nontuberculous O
mycobacterial O
infection O
, O
or O
smoking O
. O
The O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
revealed O
diffuse B-Detailed_description
bilateral B-Detailed_description
crackles B-Sign_symptom
. O
She O
suffered O
from O
severe B-Severity
hypoxemia B-Sign_symptom
( O
pH B-Diagnostic_procedure
7.362 B-Lab_value
, O
PCO2 B-Diagnostic_procedure
35.1 B-Lab_value
mmHg I-Lab_value
, O
PO2 B-Diagnostic_procedure
61.0 B-Lab_value
mmHg I-Lab_value
, O
HCO3 B-Diagnostic_procedure
- I-Diagnostic_procedure
20.1 B-Lab_value
mmHg I-Lab_value
, O
BE B-Diagnostic_procedure
-5.5 B-Lab_value
mmHg I-Lab_value
, O
SpO2 B-Diagnostic_procedure
90.5 B-Lab_value
% I-Lab_value
, O
under B-Lab_value
10 I-Lab_value
L I-Lab_value
O2/min I-Lab_value
, O
reservoir B-Detailed_description
mask I-Detailed_description
) O
. O
After O
the O
tracheal B-Biological_structure
intubation B-Therapeutic_procedure
, O
100 O
mL O
of O
bright-red O
blood B-Biological_structure
was O
aspirated B-Sign_symptom
. O
A O
chest B-Biological_structure
radiograph B-Diagnostic_procedure
showed O
bilateral B-Detailed_description
infiltrates B-Sign_symptom
( O
Fig. O
1 O
) O
. O
A O
chest B-Biological_structure
CT B-Diagnostic_procedure
further O
demonstrated O
multiple B-Detailed_description
consolidations B-Sign_symptom
and O
ground O
glass O
opacity B-Sign_symptom
and O
focal B-Detailed_description
bronchiectasis B-Disease_disorder
in O
right B-Biological_structure
segment I-Biological_structure
4 I-Biological_structure
( O
S4 B-Biological_structure
) O
( O
Fig. O
2 O
) O
. O
There O
were O
no O
space-occupying B-Detailed_description
lesions B-Sign_symptom
. O
Four B-Date
days I-Date
after I-Date
admission O
, O
her O
respiratory B-Diagnostic_procedure
condition I-Diagnostic_procedure
was O
improved B-Lab_value
. O
Since O
there O
was O
no O
active B-Detailed_description
hemorrhaging B-Sign_symptom
from O
the O
tracheal B-Therapeutic_procedure
tube I-Therapeutic_procedure
, O
she O
was O
then O
extubated B-Therapeutic_procedure
. O
After O
that O
, O
only O
a O
small B-Severity
amount I-Severity
of O
bloody B-Detailed_description
sputum B-Sign_symptom
was O
coughed O
up O
. O
To O
determine O
the O
origin O
of O
bleeding O
, O
she O
underwent O
contrast-enhanced B-Detailed_description
CT B-Diagnostic_procedure
, O
which O
showed O
bronchiectasis B-Disease_disorder
in O
right B-Biological_structure
S4 I-Biological_structure
and O
regression O
of O
the O
infiltration B-Sign_symptom
. O
CTA B-Diagnostic_procedure
revealed O
an O
abnormal B-Detailed_description
vascular B-Biological_structure
anastomosis B-Disease_disorder
between O
the O
right B-Biological_structure
inferior I-Biological_structure
phrenic I-Biological_structure
artery I-Biological_structure
and O
right B-Biological_structure
pulmonary I-Biological_structure
artery I-Biological_structure
beside O
the O
focal B-Detailed_description
bronchiectasis B-Disease_disorder
at O
the O
right B-Biological_structure
middle I-Biological_structure
lobe I-Biological_structure
( O
Fig. O
3 O
) O
, O
which O
led O
us O
to O
suspect O
it O
as O
the O
possible O
source O
of O
the O
massive B-Severity
hemoptysis B-Sign_symptom
. O
We O
therefore O
performed O
embolization B-Therapeutic_procedure
by O
superselecting B-Therapeutic_procedure
the O
right B-Biological_structure
inferior I-Biological_structure
phrenic I-Biological_structure
artery I-Biological_structure
with O
a O
2.2-Fr B-Detailed_description
. I-Detailed_description
microcatheter B-Detailed_description
( O
Fig. O
4 O
) O
. O
An O
angiogram B-Diagnostic_procedure
of O
the O
right B-Biological_structure
bronchial I-Biological_structure
artery I-Biological_structure
showed O
no O
obvious O
active B-Detailed_description
bleeding B-Sign_symptom
. O
Three B-Date
weeks I-Date
after I-Date
the O
embolization O
, O
she O
was O
successfully O
discharged B-Clinical_event
and O
has O
been O
free O
from O
recurrent B-Detailed_description
hemoptysis B-Sign_symptom
for O
three O
years O
. O
A O
34-year-old B-Age
woman B-Sex
, O
1 O
week O
postpartum O
, O
presented B-Clinical_event
to O
our O
dermatology B-Nonbiological_location
clinic I-Nonbiological_location
with O
an O
intensely B-Severity
pruritic B-Detailed_description
generalized B-Detailed_description
rash B-Sign_symptom
. O
Two B-Date
days I-Date
after I-Date
delivery B-Clinical_event
of I-Clinical_event
her I-Clinical_event
child I-Clinical_event
, O
the O
patient O
developed O
an O
itchy B-Detailed_description
rash B-Sign_symptom
on O
the O
abdomen B-Biological_structure
. O
On O
discharge B-Clinical_event
, O
she O
was O
instructed O
to O
follow O
up O
with O
the O
dermatology O
department O
if O
the O
rash O
did O
not O
resolve O
. O
After O
leaving O
the O
hospital O
, O
she O
reported O
that O
the O
eruption B-Sign_symptom
had O
progressively B-Detailed_description
spread I-Detailed_description
to O
the O
buttocks B-Biological_structure
and O
legs B-Biological_structure
and O
the O
itching B-Sign_symptom
seemed O
to O
be O
worse O
. O
The O
patient O
's O
prenatal B-Sign_symptom
course I-Sign_symptom
was O
uneventful B-Lab_value
. O
She O
gained B-Sign_symptom
13 B-Lab_value
kg I-Lab_value
during B-Detailed_description
pregnancy I-Detailed_description
, O
with O
a O
prepregnancy B-Detailed_description
weight O
of O
72 O
kg O
. O
A O
healthy B-Detailed_description
male B-Detailed_description
neonate O
was O
delivered O
by O
caesarean B-Therapeutic_procedure
section I-Therapeutic_procedure
at B-Lab_value
38 I-Lab_value
weeks I-Lab_value
' I-Lab_value
gestation I-Lab_value
without O
complication B-Sign_symptom
. O
The O
patient O
's O
medical O
history O
was O
unremarkable O
. O
She O
was O
currently O
not O
taking O
any O
medications O
, O
and O
she O
reported O
no O
known O
drug B-Sign_symptom
allergies I-Sign_symptom
. O
On O
physical B-Diagnostic_procedure
examination I-Diagnostic_procedure
, O
the O
patient O
was O
afebrile B-Sign_symptom
and O
her O
blood B-Diagnostic_procedure
pressure I-Diagnostic_procedure
was O
normal B-Lab_value
. O
Examination B-Diagnostic_procedure
of I-Diagnostic_procedure
the I-Diagnostic_procedure
skin I-Diagnostic_procedure
revealed O
erythematous B-Detailed_description
papules B-Sign_symptom
and O
urticarial B-Detailed_description
plaques B-Sign_symptom
involving O
the O
abdominal B-Biological_structure
striae I-Biological_structure
with O
periumbilical B-Biological_structure
sparing I-Biological_structure
. O
Similar O
lesions B-Sign_symptom
were O
noted O
on O
the O
legs B-Biological_structure
and O
buttocks B-Biological_structure
( O
Fig. O
1a O
) O
. O
The O
face B-Biological_structure
, O
palms B-Biological_structure
, O
and O
soles B-Biological_structure
were O
uninvolved B-Sign_symptom
. O
No O
vesicles B-Sign_symptom
or O
pustules B-Sign_symptom
were O
noted O
. O
Based O
on O
the O
characteristic O
clinical O
presentation O
and O
disease O
course O
, O
she O
was O
diagnosed O
with O
PUPPP B-Disease_disorder
. O
She O
was O
informed O
of O
the O
safety O
profile O
and O
potential O
benefits O
of O
medications O
but O
remained O
reluctant O
to O
use O
medications O
during O
lactation O
, O
despite O
her O
severe O
symptoms O
. O
AWB B-Therapeutic_procedure
injection I-Therapeutic_procedure
was O
then O
considered O
for O
her O
treatment O
. O
Venous B-Biological_structure
blood I-Biological_structure
of O
10 O
mL O
was O
drawn B-Therapeutic_procedure
from O
the O
patient O
, O
followed O
by O
intramuscular O
injection B-Therapeutic_procedure
of O
5 O
mL O
of O
the O
blood B-Biological_structure
on O
each B-Biological_structure
side I-Biological_structure
of I-Biological_structure
her I-Biological_structure
buttock I-Biological_structure
. O
Seven B-Date
days I-Date
later I-Date
, O
both O
subjective O
and O
objective O
improvements B-Lab_value
of O
symptoms B-Sign_symptom
were O
noticed O
and O
she O
received O
1 B-Lab_value
more I-Lab_value
session I-Lab_value
of O
AWB B-Therapeutic_procedure
injection I-Therapeutic_procedure
( O
Fig. O
1b O
) O
. O
On O
follow-up O
after B-Date
12 I-Date
days I-Date
, O
all O
subjective O
symptoms B-Sign_symptom
had O
improved B-Lab_value
, O
leaving O
only O
postinflammatory B-Detailed_description
hyperpigmentation B-Sign_symptom
( O
Fig. O
1c O
) O
. O
No O
complications O
such O
as O
infection B-Sign_symptom
, O
abscess B-Sign_symptom
formation O
, O
or O
hematoma B-Sign_symptom
were O
observed O
at O
the B-Biological_structure
injection I-Biological_structure
site I-Biological_structure
. O
